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ABSTRACT 
The critical role of cysteine import and metabolism in pancreatic cancer 
Michael Alexander Badgley 
 
 As of this writing, pancreatic cancer is the third leading cause of cancer-related death in 
the United States: approximately 53,670 new cases will be diagnosed in 2017. Of those patients 
living with this disease, 43,090 are estimated to die in 2017, accounting for an astounding 7.2 % 
of all cancer deaths. In fact, pancreatic cancer is estimated to rise to the second leading cause 
of cancer-related death in the United States by 2020, since it is one of the few cancers for which 
incidence is currently increasing over time. While precious gains have been made over the past 
40 years to improve the survival rates of patients with this disease, still only 8.2% of patients will 
survive 5 years beyond their initial diagnosis, highlighting the need for researchers and 
clinicians to develop novel therapeutic strategies for what has heretofore been a highly 
intractable malignancy. 
 Recent efforts in the field of pancreatic cancer research have focused on identifying new 
biological dependencies in this cancer that may be leveraged to improve treatments. Many of 
these dependencies revolve around the unique metabolic demands of the cancer cell, 
highlighted in work first popularized in 1956 by Otto Warburg. New research has demonstrated 
that one of these unique metabolic demands may in fact be the tight regulation of redox 
homeostasis, spurred by the need of metabolically active pancreatic cancer cells to detoxify 
naturally occurring reactive oxygen species (ROS) in order to maintain a healthful state. 
Experiments have shown that activating mutations in KRAS, which are present in 95% of 
pancreatic cancers, actually created a highly reducing intracellular environment to support the 
increased proliferative capacity of these cells. 
 Many cellular processes have evolved to cope with the stress of ROS production. Most 
 
of these functions revolve around the unique chemistry of thiol functional groups, which are 
highly reactive and exquisitely sensitive to oxidation. Only two of the twenty canonical amino 
acids can provide the sulfur necessary for this chemistry: cysteine and methionine. Cysteine is 
the more reactive of these two amino acids and as such provides the basis for much of the 
redox chemistry of the cell. This is accomplished through its role as the rate-limiting precursor 
for the synthesis of glutathione which is the preeminent antioxidant molecule of the cell. To 
explore the possibility that the perturbation of redox homeostasis may present a unique 
therapeutic avenue in the context of pancreatic cancer cells, we have endeavored to illuminate 
the role of cysteine and its metabolic derivatives in maintaining the redox state of pancreatic 
cancer cells.  
 Here, we show that cysteine is critical for the growth of multiple pancreatic cancer cell 
lines, preventing the rapid and catastrophic accumulation of ROS, particularly lipid ROS. In the 
absence of exogenously provided cysteine, the quick accumulation of lipid ROS causes a cell 
death phenotype previously described as “ferroptosis,” an iron-dependent, oxidative process. 
We also confirm that these effects can be mimicked pharmacologically by treating these cells 
with agents that block system xc
-, the only known transport mechanism of oxidized cysteine 
(cystine). In addition, we identify cells that exhibit a priori resistance to these effects, but which 
can be sensitized to ferroptotic cell death by blocking macropinocytosis, an endocytic process 
that facilitates the bulk uptake of large extracellular substrates into the cell. Finally, we show that 
GSH depletion is required, but not sufficient to mediate these effects, suggesting that additional 
cysteine-derived metabolites provide secondary functions critical to protecting against 
ferroptosis. 
To explore whether these effects also hold true in vivo, we first assessed the mRNA 
expression levels of SLC7A11, a gene that encodes a protein subunit specific to system xc
-. We 
demonstrate that SLC7A11 is specifically upregulated in malignant pancreatic cancer tissue 
 
when compared to a normal counterpart. Furthermore, this gene is upregulated as the cancer 
progresses from pre-neoplastic lesions to frank carcinoma. Also, we highlight that this gene is 
upregulated in other cancers as well, suggesting broadly applicable therapeutic potential. 
Finally, to test if this system can be targeted in vivo, we designed a genetically engineered 
mouse model of pancreatic cancer in which we can temporally control the deletion of SLC7A11. 
Using this tool, we demonstrate that deletion of SLC7A11 in the context of established 
pancreatic tumors can retard and even regress tumor growth, resulting in a notable increase in 
overall median survival. Taken together, our results indicate that cysteine import and 
metabolism are a critical dependency in pancreatic cancer, providing evidence that targeting 
these mechanisms may be useful in a clinical setting.
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Pancreatic Cancer: History, epidemiology, biology, and models 
History 
In antiquity, anatomy was already a highly refined science, albeit a grotesque one. Some 
ancient anatomists have even been accused by historians of performing live vivisections on 
local criminals1. One such anatomist, the so-called “Father of Scientific Anatomy,” Herophilus of 
Chalcedon, is generally credited with the first description of the pancreas in 300 BC2,3. Galen, 
the prominent Greek physician and surgeon, would later give an ambiguous assessment of the 
organ, and there is no evidence that the ancient Greeks had even a rudimentary understanding 
of the organ’s function4. Even with its formal anatomical description (Figure 1-1), the pancreas 
remained an enigmatic organ for some time: it was not until many centuries later that it would 
even be appreciated both for its critical roles in normal physiology and as a seat of diseases5. 
While the pancreas is perhaps most famous for its endocrine function and the role it 
plays in the onset of type I diabetes, as early as the 16th century, anatomical scientists did note 
that cancerous malignancies were associated with the organ. The first known description of one 
such tumor was written in 1761 by the Italian anatomist Giovanni Battista Morgagni in his 
seminal work, De Sedibus Et Causis Morborum Per Anatomen Indagatis Libri Quinque (On the 
Seat and Causes of Disease, Investigated Through Anatomy, in Five Books). In this tome, 
Morgagni set forth the first description of a mass in the pancreas available in Western medicine. 
It would take nearly 100 years before this finding would be confirmed in a series of cases 
described by Jacob Mendez Da Costa, an American clinician in Philadelphia. In a series of 
thirty-seven cases, Da Costa would describe in some detail this cancer and its associated 
effects, including its tendency to occlude the bile duct, its dense and fibrotic nature, and its 
associated co-morbidities. All these findings were set forth in his published work, On the Morbid 




Figure 1-1: The anatomy of the pancreas 
The pancreas is a retroperitoneal organ which serves both an exocrine and endocrine function. 
More than 90% of the pancreas is composed of acinar tissue tasked with the production of 
digestive enzymes to facilitate nutrient absorption in the small intestine. The endocrine function 
of the pancreas is carried out by cells in the islets of Langerhans, which produce a bevy of 
hormones to control blood glucose levels. 
  
approaches physicians and surgeons of the day would take to treat this still relatively mysterious 
illness. 
Early treatments for the disease revolved around surgical approaches. In the 19th 
century, an Italian surgeon named Alessandro Codivilla performed the first attempted 
pancreaticoduodenectomy  (resection of the head of the pancreas and the neighboring 
duodenum) to remove a mass on the head of the pancreas, only to lose his patient 18 days 
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following the operation6. The first successful pancreaticoduodenectomy would be performed by 
Georg Hirschel on a patient presenting with jaundice and suffering from an ampullary 
carcinoma. Finally in 1935, here at Columbia, the first Whipple procedure would be completed 
(so-named for the American surgeon, Allen Oldfather Whipple, who popularized the technique 
and was a professor of surgery at Columbia University from 1921 to 1946). The Whipple 
Procedure involved the removal of the C-loop of the duodenum and the pylorus junction of the 
stomach; resection of the head of the pancreas; and the ligation of the remaining pancreas, 
common bile duct, and stomach to facilitate functional digestion.  The initial attempt at this 
surgery was described in three patients. While the first patient did not survive the ordeal, the 
second patient would live for nine months, eventually dying from an inflamed gall bladder. The 
third patient would live for two years, eventually succumbing to liver metastases arising from the 
original ampullary cancer7. The Whipple Procedure would go on to become a standard 
operation for patients with pancreatic cancer in the head of the pancreas, being thoroughly 
updated throughout the years to treat tail of the pancreas tumors and to improve outcomes for 
patients throughout the world.  
Few patients, however, actually qualify for surgical interventions in pancreatic cancer 
(estimates range from 10-20% of diagnosed patients), prompting later treatments to leverage 
the discovery and use of poisonous chemotherapeutics. While initially radiotherapy was 
commonly used in the treatment of locally invasive, unresectable pancreatic cancer, pioneering 
research in 1969 showed that combinations of radiation and 5-fluorouracil (5-FU), a nucleoside 
analog, could extend survival in pancreatic cancer patients8.  This work was confirmed in 
another landmark study, showing that patients treated with radiation and 5-FU had a prolonged 
median survival of 10 months compared to 5.5 months with radiation alone9. New treatments of 
pancreatic cancer with chemotherapy would stagnate for 16 years until a trial showed 
improvements to quality of life and a modest improvement in overall survival when patients were 
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treated with gemcitabine, a cytidine analog10. Gemcitabine would remain the standard of care 
treatment for advanced pancreatic cancer for nearly 15 years until the FDA approval of the new, 
aggressive chemotherapeutic cocktail, FOLFIRINOX (a composite regimen containing folinic 
acid, 5-FU, irinotecan, and oxaliplatin) which had been shown to increase overall survival in 
metastatic pancreatic cancer from 6.8 to 11.1 months when compared to gemcitabine alone11. 
Two years later, another treatment regimen featuring gemcitabine and nab-paclitaxel, an 
albumin-bound form of taxol, would prove efficacious in metastatic pancreatic cancer patients, 
shifting median overall survival from 6.7 to 8.5 months when compared to gemcitabine alone12. 
Research continues to move apace, as researchers race to find new chemotherapeutic 
regimens to extend survival in these patients (Table 1-1). However, few patients still qualify for 
potentially curative surgery and 5-year survival rates continue to be stubbornly low, even as new 
treatments are approved, highlighting the need for new and paradigm-shifting research to 
challenge the devastation of this malignancy.  
 
 
Table 1-1: List of successful stage III clinical trials in pancreatic cancer 
In the past two decades, only five major clinical trials in metastatic pancreatic cancer have 
resulted in new, FDA-approved treatment regimens in pancreatic cancer. They are listed above 
with relevant clinical details. Even with these advances, 5-year survival rates remain low. 





% 1-year survival p-value Author (year)
5-FU 63 0.00% 4.41 2%
Gemcitabine 63 5.40% 5.65 18%
Gemcitabine 284 6.90% 5.9 17%
Gemcitabine/erlotinib 285 8.20% 3.2 23%
Gemcitabine 171 6.80% 6.8 21%
FOLFIRINOX 171 11.10% 11.1 48%
Gemcitabine 430 7.00% 6.7 22%
Gemcitabine/nab-paclitaxel 431 23.00% 8.5 35%
5-FU and folinic acid 149 1.00% 4.2 not reported
Onivyde (irinotecan) 151 6.00% 4.9 not reported 0.012 Wang-Gillam et al. (2015)
5-FU and folinic acid/Onivyde 117 19% 6.1 not reported
<.001 Hoff DD et al. (2013)
0.0025 Burris HA III et al. (1997)
0.038 Moore MJ et al. (2005)




     While the rates of death caused by cancer as a broad entity continue to decrease slowly over 
time, pancreatic cancer has the ominous distinction of being one of the few cancers that 
controvert that trend. While the current number of new cases of this cancer is 12.5 per 100,000, 
ranking it only the twelfth most common cancer in the United States, it is estimated that over 
43,000 people will die of this disease in 2017 in the US, making it the third leading cause of 
cancer related death in this country. In fact, whereas the number of deaths per 100,000 persons 
per year in the cases of lung, breast, and colon cancer (the three other leading causes of 
cancer-related death in the US) has continued to drop since 1992, pancreas cancer mortality 
has risen over the same time frame. In 2017 it is estimated that while only 3.2% of all new 
cancer cases will be pancreatic cancer, it will account for 7.2% of all cancer deaths. By 2020, 
pancreatic cancer is predicted to become the second leading cause of cancer-related deaths in 
the US, trailing only lung cancers13,14.  
These numbers alone paint a harrowing picture of the current state of the disease, but 
when analyzed alongside survival times post-diagnosis, the portrait becomes even more tragic. 
Currently, only 8.2% of patients diagnosed with pancreatic cancer will survive beyond 5 years, 
and the median survival is estimated at 3-6 months15. Of these patients, 10-20% are eligible for 
surgery, the only ostensibly curative therapy available. While resected patients see an improved 
20-25% five-year survival rate and a median survival time between 12-20 months, research has 
now shown that the majority of these patients will recur within a year16-19.  
Many of these disappointing outcomes can be traced to the staging of pancreatic cancer 
at diagnosis. Only 10% of tumors are confined to the primary site, while nearly 30% have 
already spread to local lymph nodes. Over half of the time, the cancer has already metastasized 
to distant sites. As one might expect, 5- year relative survival correlates well with stage at 
diagnosis: 31.5% for patients with localized disease; 11.5% for patients with disease having 
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spread to regional lymph nodes; and a disastrous 2.7% for patients with distant metastases. 
There is scant research to pinpoint a precise cause of pancreatic cancer, but we can say 
that age is the most obvious risk factor. The disease primarily afflicts persons between ages 65-
74, with this age group accounting for the plurality of new cases (27.8%). Most cases occur in 
patients over the age of 65, with 70 being the median age of diagnosis. That is not to say that 
the cancer cannot effect younger populations, though: 10% of cases are diagnosed in patients 
under the age of 54. Other more operable risk factors have been identified, including but not 
limited to cigarette smoking, heavy metal exposure, alcohol use, obesity, chronic pancreatitis, 
and family history20-23. Aspirin is known to decrease risk. These data paint a complicated 
epidemiological picture of a devastating disease, highlighting the need for improved screening 
techniques and treatment options for this cancer. 
Biology 
While pancreatic cancer continues to be a distressing diagnosis across the globe, 
illuminating research has eliminated some of the mystique this disease once held. While the 
molecular and biologically diverse functions of the pancreas can actually give rise to multiple 
pancreatic cancer types, we will restrict our discussion to by far the most common form of the 
disease: pancreatic ductal adenocarcinoma (PDA). PDA, so named due to its sharing 
histological features with ductal structures of the pancreas, accounts for more than 85% of 
pancreatic cancers24,25. PDA is characterized by glandular structures bearing strong 
resemblance to the epithelium of the ducts of the pancreas and a dense and desmoplastic 
stroma surrounding these structures (Figure 1-2)26. Tumors exhibit a wide range of 
differentiation states, from very glandular to highly mesenchymal. Often, these tumors invade 
local nerve bundles and lymph nests, spreading through the hematological system to invade 




Figure 1-2: PanIN progression model of pancreatic cancer 
Pictured above is the current working model for the development of pancreatic cancer from 
PanIN precursor lesions. Mutations in the oncogene KRAS, highlighted in red, occur at the 
earliest stage of preneoplastic development and are thought to be critical for the development 
and maintenance of this disease. Histological images below each stage indicator typify the 
morphological features of these lesions and of PDA. 
Adapted from Adapted from Hruban et al. 2003, Hingorani et al. 2003, Vincent et al. 2011, and 
Olive et al. 200629-32 
 
Pancreatic cancer is now known to arise from multiple forms of precursor lesions, the 
most common of these being pancreatic intraepithelial neoplasms, or PanINs33. While these 
lesions are common in older adults, only a subset of these preneoplasms will transform into fully 
invasive carcinoma. PanIN lesions progress through three stages: PanIN-1 lesions are 
characterized by columnar, mucinous accumulations in ductal structures containing relatively 
normal nuclei; PanIN-2 lesions exhibit epithelial folding structures and nuclear atypia; PanIN-3 
lesions contain increasingly irregular nuclei and display epithelial budding into the luminal 
space. PanIN-3 neoplasms are considered carcinoma in situ, or cancer which has not yet 
managed to breach the basement membrane of the epithelium34. 
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From a molecular genetic standpoint, pancreatic cancer has been very well studied. 
Early events include activating mutations in KRAS and functional loss of the CDKN2A locus. 
Subsequently, some precancerous cells will acquire loss-of-function mutations in p53, SMAD4, 
and BRCA2 (all tumor suppressor genes). Most commonly, however, the cancer is associated 
with its earliest genetic lesion, activating mutations in KRAS, which are present in 95-100% of 
all PDA cases35,36. The most common KRAS mutations in PDA occur at codon 12, however 
other prevalent mutations include those at codons 13 and 6037. These mutations limit the ability 
of KRAS to carry out its GTPase function or to bind GTPase activating proteins, leaving the 
protein bound to GTP and thereby in its active signaling state38. The resulting signaling cascade 
is thought to precipitate many of the oncogenic events that give rise to pancreatic cancer. Given 
the early timing of this mutation in PDA, it has been the subject of intensive study over many 
decades. Results have shown that activating KRAS mutations play a critical role in both the 
initiation and maintenance of PDA39,40, making it an attractive pharmacological target in this 
disease. To date, however, attempts to drug mutant KRAS directly have proven difficult due it its 
nature as a small GTPase and its lack of structurally appropriate binding pockets41. Recent 
efforts using in silico approaches have proven, however, that mutant RAS is targetable42. 
Since drugging KRAS directly has not borne clinical fruit as of yet, many researchers 
have focused studies on understanding downstream biological implications of KRAS mutation in 
order to leverage possible dependencies precipitated by these mutations. One such burgeoning 
field of study has revolved around understanding the critical metabolic shifts initiated by KRAS 
mutation in cancer. Consequently, altered metabolic function is newly emerging as a well-
appreciated hallmark of cancer43, although it may be better to say that this concept is actually 
re-emerging. As many as 60 years ago, Otto Warburg famously contended that cellular 
metabolic shifts from primarily mitochondrial oxidative phosphorylation to aerobic glycolysis 
were actually the cause of cancer. And, while most researchers now contend that these 
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phenotypes, the so-called “Warburg Effect,” are the result of changes in cancer cells rather than 
their cause, Warburg’s hypothesis has continued to be the basis for a renewed and expansive 
interest in metabolic biology in the context of cancer.  
Given that the vast preponderance of PDAs harbor activating KRAS mutations, many 
studies have focused on elucidating the myriad metabolic shifts that occur in RAS-mutant 
cancer cells (Figure 1-3). Current work suggests that many of the metabolic shifts in these cells 
occur to support a high rate of proliferation by facilitating the production of adequate levels of 
cellular biomass substrates, including proteins, lipids, and DNA44. Interestingly, PDA is generally 
considered nutrient-poor, thanks in part to its deposition of a stifling desmoplastic stroma45. This 
results in PDA utilizing novel methods to accumulate biomolecular building blocks, including by 
using autophagy and macropinocytosis46-48. To acquire essential amino acids, some research 
suggests that PDA in patients can cause body-wide metabolic reprogramming, sending 
branched-chain amino acids into circulation via whole-body muscle protein breakdown and that 
this process even precedes disease diagnosis by as many as 5 years49. To acquire the 
molecular precursors necessary for the production of both lipids and DNA, PDA cells grow 
addicted to glutamine consumption. Glutamine, an incredibly metabolically flexible molecule, 
provides carbon for the TCA cycle, nitrogen for the production of purine and pyrimidine rings of 
DNA bases, and contributes to the synthesis of CoA to support lipid production50-54. 
In addition to increasing biomass needs, high rates of cellular proliferation can cause an 
accumulation of reactive oxygen species (ROS) caused by mitochondrial respiration in both 
precancerous lesions and PDA55-58. ROS, while natural byproducts of mitochondrial respiration, 
are highly reactive molecules than can damage proteins, lipids, and DNA. To combat this, 
mutant KRAS pancreatic cancer cells create a uniquely reducing intracellular environment by 




Figure 1-3 Metabolic changes in cells associated with activating RAS mutations 
Multiple metabolic shifts occur in RAS-mutant cancer cells. Classically, RAS mutations cause an 
increase an aerobic glycolysis, the “Warburg effect,” resulting in the production of pyruvate and 
lactate from glucose (left). RAS-mutant cells are also addicted to glutamine, using this flexible 
biomolecule to create substrates for the TCA cycle and also maintain a healthy redox state 
(center). RAS-mutant cells can upregulate macropinocytosis, an endocytic cellular process, 
allowing them to take up large extracellular components, which are then transported to the 
lysosome for the breakdown and release of their constituent amino acids (right, bottom). Mutant 
RAS pancreatic cancer cells also activate autophagy to catabolize damaged organelles and 
proteins for reuse in essential biomolecular processes (right, top). Metabolic enzymes regulated 
by mutant RAS are highlighted in blue, with arrows indicating up or down regulation. Enzymes in 
yellow are not known to be affected by mutant RAS.  
Abbreviations: GLUT1, glucose transporter-1; HK1 and HK2; hexokinase 1 and 2; PFK1, 
phosphofructokinase 1; ENO1, enolase1; PKM, pyruvate kinase; LDHA, lactate dehydrogenase; 
GLUD1, glutamate dehydrogenase 1; GLS1, glutaminase 1; GOT1 and 2; aspartate 
transaminase 1 and 2; MDH1, malate dehydrogenase 1; ME1, malic enzyme 1 
Figure adapted from Cox et al., 201460 
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 these cells on a highly reducing environment to promote tumor formation and maintenance in 
spite of the increased production of ROS, may represent a critical opportunity for highly specific 
and potent targeting of this disease, which we will expound on in later chapters of this work. 
 Models 
While clinical research has continued apace on pancreatic cancer patients since the 
1960’s, models that would allow researchers to delicately interrogate specific aspects of PDA 
biology in vivo would not arise until the early 2000’s (Table 1-2). Although early models of the 
1980’s used harsh carcinogens to facilitate the production of pancreatic tumors in mice61,62, it 
was the creation of the Cre-inducible KRASLSL-G12D allele in 2001 that would revolutionize the  
 
Table 1-2 Genetically engineered mouse models of pancreatic cancer 
Listed above are some of the most commonly employed genetically engineered mouse models 
(GEMMs) in the field of pancreatic cancer.  
Abbreviations: PanIN, pancreatic intraepithelial neoplasia; PDA, pancreatic ductal 
adenocarcinoma; ACC, adenoid cystic carcinoma 
Genotype PanINs? Time to cancer onset Cancer type Metastasis? Median Survival Comments
Pdx1-Cre;KrasG12D Yes Over a year PDA Yes Over a year
Early model of PDA, 
though only a subset of 
mice develop cancer
p48+/Cre;KrasG12D Yes Over a year PDA Yes Over a year
Very similar to Pdx1-
Cre;KrasG12D mouse; p48 
expression is less leaky
Pdx1-
Cre;KrasG12D;p53lox/lox
Yes 1-2 months PDA No 3 months




Yes 2-3 months PDA Yes 5 months
Recapitulates the 
phenotypic constellation 
of the human disease
Ptf1a+/Cre;KrasG12D;p53R
270H/+;Brca2Tr/D11
Yes 2 months PDA, ACC Yes 2.5 months





creation of genetically engineered mouse models (GEMMs) in this disease63. The unique 
scientific achievement of this allele was the utilization of the “Lox-stop-lox” cassette (the “LSL” of 
the abbreviation above), which prevented the expression of the constitutively active mutant 
KRAS allele until this DNA was brought into the proximity of Cre-recombinase. Tissue specific 
drivers of Cre expression were already available by this time, allowing researchers spatial 
control of the activation of this oncogenic allele. In 2003, work was published characterizing 
what is now commonly referred to as the KC model, in which either PDX-Cre or p48-Cre (both 
pancreas-specific transcription factors) mice are bred with KRASLSL-G12D mice to create KC 
mice30. Remarkably, these mice are born with relatively normal pancreata but later develop PDA 
deriving from precursor PanIN lesions, albeit at low penetrance.  
 The KC model, while highly informative and continuingly useful, develops malignant 
tumors at too low a frequency and too slow a rate for preclinical research utility. To surmount 
this shortcoming, additional genetic modifications have been layered onto this mouse. The first 
description of what would become for many the current standard in GEMMs of PDA came only 
two years after the description of the KC mouse. These mice, KRASLSL-G12D; p53LSL-R172H; 
PdxCre, aptly termed KPC mice, develop precursor PanIN lesions more quickly than KC mice, 
and develop focal pancreatic tumors with 100% penetrance64. Importantly, KPC mice 
recapitulate many aspects of the human disease with high fidelity, including the presence of 
distant metastases to the liver, lungs, and peritoneum; and widespread chromosomal instability 
in the genomes of tumor cells. Histopathologically, they express markers found in human PDA 
and are characterized by the same densely fibrotic stroma seen in human patients. As such, 
they serve as the primary reagent in translational studies hoping to elucidate the relevance of 
interrogated pathways to clinical application and form the basis for the mouse model discussed 
in Chapter 5. 
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Cysteine: Functions and Transport 
Function 
 Discovered first in its dimeric form (cystine) in 1810 by the chemist William Hyde 
Hollaston65, and later in its monomeric form (cysteine) in 188466, cysteine has long held a 
unique place in amino acid biology (Figure 1-4). Considered a semi-essential amino acid, it is 
the preponderant source of free sulfur in mammalian cells. As a result, cysteine plays a critical 
role in many, indispensable biological processes. The highlight of its structure is its highly 
reactive thiol group, which is readily oxidized and can act as a potent nucleophile in many 
enzymatic processes. The only other amino acid to contain sulfur is methionine, which can act 
as a sulfur-donor in the biosynthesis of cysteine through the transsulfuration pathway, but which 
itself is not particularly a reactive molecule. Thanks is no small part to the reactivity of its 
sulfhydryl group, cysteine can be considered the primary amino acid responsible for stabilizing 
secondary and tertiary protein structure, facilitated by the oxidation of this thiol group and the 
formation of covalent disulfide bridges. Cysteine residues also serve a critical functional role in 
many proteins, acting as unique sensors of oxidative stress67 and dynamically regulating 
enzyme function in response to changes in intracellular redox state.  
 Clearly, cysteine is vital for the role it plays in protein synthesis and structure, but it is 
perhaps equally appreciated for its more general antioxidant properties. The active thiol group 
can provide the reducing equivalents necessary for the neutralization of ROS, classically doing 
so in the form of glutathione (GSH), the preeminent non-protein antioxidant of the cell. GSH is 
synthesized in two enzymatic steps: first, the protein glutamate-cysteine ligase (GCL) catalyzes 
the condensation of glutamate and cysteine to form gamma-glutamylcysteine; second, 
glutathione synthetase (GSS) catalyzes the creation of glutathione by adding glycine to the 
product of the previous step. Cysteine is considered the rate-limiting precursor to the synthesis  
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Figure 1-4 The structure of cysteine and cystine 
The semi-essential amino acid cysteine can readily be oxidized to from its dimer, cystine. The 
dimer is formed by the creation of a disulfide bond between two free cysteine molecules. The 
sulhdryl group, highlighted here in gold, is the bioreactive portion of the molecule, lending it the 
capacity for many of its vital functions. 
 
of GSH primarily due to its relative intracellular scarcity when compared to glutamate and 
glycine. From a functional perspective, it is the sulfur provided by cysteine that acts as the 
bioactive portion of GSH, donating electrons to stabilize ROS and subsequently binding another 
oxidized GSH to form GSSG. GSSG can then be recycled by glutathione reductase at the 
expense of NADPH to give rise to GSH once more. Through GSH, cysteine can be considered 
one of the most potent molecules responsible for redox homeostasis in mammalian cells. 
 Cysteine also serves as a component of the biosynthesis of Coenzyme A (CoA), which 
is critical for the creation and oxidation of lipids. CoA plays an important role in the synthesis of 
HMG-CoA from acetyl-CoA and acetoacetyl-CoA. HMG-CoA is a precursor to the production of 
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mevalonate, the critical substrate from which cholesterol and other isoprenoids are synthesized, 
contributing to lipid synthesis and overall cell health. Furthermore, cysteine serves important 
bioenergetic functions by indirectly giving rise to increased pyruvate production through its 
degradation. Cysteine can be degraded, beginning with its oxidation by cysteine dioxygenase to 
yield 3-sulfinoalanine. This molecule can then be transaminated to yield 3-sulfinopyruvate, 
which will quickly degrade to pyruvate and sulfite. Pyruvate is then free to enter the TCA cycle in 
metabolically active cells. Taken together, cysteine plays a unique role in protein function, redox 
homeostasis, and even cellular bioenergetics—all functions that underscore the fascination that 
chemists and biologists have had with cysteine for more than 200 years. 
Transport 
 As highlighted previously, cysteine exists in two forms depending on oxidation state: as 
a monomer (cysteine) or as a dimer joined by a disulfide bond (cystine). Reduced cysteine can 
be imported into the cell primarily through the sodium-dependent ASC system, which also 
favors the transport of alanine, serine, and threonine68,69. System ASC is widely expressed in 
various tissues and cell types, modulating its affinity for certain transport candidates across 
species and even based on cellular context70-72. It should be noted, however, that most cysteine 
in the extracellular space is present in its oxidized form, cystine, and thus System ASC accounts 
for a low percentage of total cysteine import in cells73. 
Cystine import into cells is facilitated by the heterodimeric transporter, system xc
-. 
Composed of two subunits, the heavy chain subunit SLC3A2 and the light chain subunit 
SLC7A11, system xc
- pairs the import of cystine with the export of glutamate at a one-to-one 
molar ratio. Of its two component subunits, SLC3A2 is common to many amino acid 
transporters, whereas SLC7A11 is specific to this transporter74,75. Given its specificity, SLC7A11 
has been of particular interest functionally since perturbation of its expression impedes the 
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function of cystine import precisely. Located on chromosome 4 in humans and chromosome 3 in 
mice, the SLC7A11 gene contains 12 transmembrane domains and is expressed in a wide array 
of tissues, including the nervous system, liver, lung, and pancreas. The expression of this 
transporter is thought to be tightly regulated by levels of extracellular glutamate, amino acid 
starvation, and oxidative stress.  Naturally occurring mutations of SLC7A11 are found in the 
subtle gray (sut) mouse, so-named due to its characteristic gray coat. Impressively, that 
absence of functional transporter in the sut mouse produces relatively mild phenotypes, 
including increased bleeding time, higher sensitivity to chemical carcinogens, and discolored 
skin and coat pigmentation. Otherwise, these mice seem to fare quite well. SLC7A11 knockout 
mice have also been generated and exhibit mild neurological phenotypes, but otherwise normal  
Figure 1-5 Structure of SLC7A11 
SLC7A11 is the gene encoding the specific subunit of the heterodimeric system xc
- antiporter. 
Located on chromosome 3 in mice, the gene contains 12 exons (E), spanning 134,151 base 
pairs. The naturally occurring mutation in sut mice deletes the entirety of exon12 and more 
neighboring DNA.  
 
lifespans. While it is known that system xc
- can be targeted pharmacologically in culture, no 
conditional models of SLC7A11 deletion had yet been created or studied prior to this work, 
previously limiting our ability to study the transport of cystine in vivo. 
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Ferroptosis: Mechanism and Clinical Relevance 
Mechanism 
Understanding how and why cells die has been a field of active research dating back to 
the 19th century, but the notion that cell death can be tightly biologically regulated was an 
epiphany reserved for the mid-20th century. The term “apoptosis,” deriving from the Greek term 
to describe a “falling off”, as a petal from a flower or a leaf from a tree, was first coined in 1972. 
While apoptosis had actually been identified in principle over one hundred years before, it would 
only become the thriving field of research it is today once it was discovered that this process 
was precisely regulated molecularly and it was dysregulated in some human diseases, notably 
in cancer.  
Apoptosis, by far the most famous and well-studied cell death mechanism, has 
nourished a wide field of research now extending into intriguing, new mechanisms of cell death: 
among these, autophagic cell death, necrosis, necroptosis (programmed necrosis), and 
ferroptosis. Ferroptosis will be the focus of this discussion because of its close ties to oxidative 
stress, cystine import, and GSH: all major subjects of this work. Ferroptosis is an iron-
dependent, oxidative form of cell death characterized morphologically by membrane 
“ballooning” coupled with the presence of relatively intact nuclei. First formally described in 
2013, ferroptosis is genetically and morphologically distinct from apoptosis, autophagic cell 
death, and necroptosis mediated by RIPK1.The first compounds found to cause ferroptosis 
were initially identified in large chemical library screens targeting RAS-mutant cell lines. These 
compounds, termed erastin and RSL3, targeted system xc
- and glutathione peroxidase 4 
(GPX4), respectively, providing evidence that ferroptosis could be achieved through 
mechanistically distinct means. It is currently thought, however, that the primary effector of 
ferroptotic cell death is the compromised function of GPX4, whether directly (e.g. RSL3), or 
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indirectly by GSH depletion (e.g. erastin and BSO). In either situation, the cell’s inability to 
detoxify lipid ROS results in catastrophic damage to cellular membranes, causing the resultant 
cell death phenotype (Figure 1-6). 
 Functionally, ferroptosis is identified by the accumulation of damaging lipid ROS and its 
dependence on large pools of available iron. Lipophilic antioxidants including Trolox (a water-
soluble vitamin E analog), α-tocopherol, and β-carotene have all been shown to potently rescue 
ferroptotic cell death, implicating lipid ROS as the primary mediators of this process.  
 
Figure 1-6 Model of ferroptosis in KRAS mutant cells 
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Furthermore, deferoxamine (DFO), a powerful iron chelator, is able to protect cells otherwise 
sensitive to ferroptosis from death. Iron is a critical cofactor for the production and propagation 
of free radicals via the Fenton reaction. In fact, it is this dependence on iron from which 
ferroptosis derives its name (“ferrum,” latin for iron). To date, ferroptotic cell death is confirmed 
through either rescue by lipophilic antioxidant or iron chelation. 
Clinical relevance 
 Much of the current data characterizing ferroptosis details its mechanistic underpinnings, 
but a burgeoning corner of the field is beginning to address critical questions determining the 
relevance that this cellular process might play in human diseases. Recent work has used 
ferostatin-1, the current canonical inhibitor of ferroptosis, to rescue the deleterious effects of 
pathogenic huntingtin protein in a brain slice model, the effects of cystine deprivation on 
cultured oligodendrocytes in a model of periventricular luekomalacia, and the cell death seen in 
models of rhabdomyolysis-induced kidney injury. Of critical importance for the work we lay out 
here, ferroptosis has been shown to occur in some cancer types, including cell culture models of 
diffuse large B cell lymphoma. However, better models are still needed to address whether 
ferroptosis truly can occur in vivo in the context of disease—a major aspect of the field pushed 




























Background and Significance 
Current treatment for metastatic PDA is based primarily on cytotoxic chemotherapeutic 
combinations. While increasingly aggressive regimens have produced modest increases in 
overall survival, only a small minority of tumors harbor “actionable” genetic alterations targeted 
by current precision medicine paradigms76. There is a great need for novel, translatable 
approaches for this disease. In recent years, a number of groups have revitalized the study of 
cancer metabolism with a focus on cancer–specific dependencies that might be amenable to 
therapeutic intervention. Notable examples include preferential reliance on serine to provide 
intermediates for the 1-carbon cycle 77, aspartate aminotransferase (GOT1) for the production of 
NADPH  in pancreatic cancer 54, IDH1 mutations for the production of 2-hydroxyglutarate in a 
subset of gliomas 78, glutathione (GSH) synthesis in breast cancer79, and glutamine addiction50. 
Metabolic dependencies often vary by cancer type, but generally reflect the dominantly anabolic 
needs of tumor cells for generating the raw materials required for cell proliferation.  
Recent work has shown that mutant KRAS, the oncogene most typically associated with 
pancreatic cancer development and maintenance, results in a cascade of metabolic changes 
that may offer therapeutic opportunities80. Interestingly, mutant KRAS was shown to create a 
highly reducing intracellular environment in pancreatic cancer cells by promoting the 
overexpression of Nrf2, a transcription factor controlling the activity of antioxidant genes 59. 
While redox biology seems to be a critical component of the development and maintenance of 
PDA and other cancers, efforts to translate agents such as buthionine sulfoxamine (BSO), an 
inhibitor of GSH synthesis, have not been successful. A greater understanding of the specific 
metabolic pathways that contribute to redox hemostasis in PDA is warranted.  
In this chapter we explore the hypothesis that redox homeostasis represents a critical 
dependency in pancreatic cancer cells. We find that cysteine, being one of only two biological 
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sources of the fixed sulfur required for most antioxidant processes, is critical to PDA cell 
proliferation and survival. When deprived of cysteine by exogenous removal, pancreatic cancer 
cells die very quickly, exhibiting morphology characterized by a membrane “ballooning:” effect 
while maintaining relatively intact nuclei. We also show that these effects can be phenocopied 
by inhibition of system xc
-. Characterizing this cell death phenotype, we conclude that cysteine 
deprivation causes ferroptosis in pancreatic cancer cells, characterized by early accumulation of 
lipid ROS and rescuable by lipophilic antioxidants and the iron chelator DFO.  These 
experiments show, for the first time, that pancreatic cancer cells require cysteine for viability. 
Results 
PDA cell lines are sensitive to cysteine withdrawal 
Cysteine is a semi-essential amino acid that plays a critical role in intracellular redox 
homeostasis owing to its uniquely reactive sulfhydryl group, which provides reducing 
equivalents necessary for the function of many antioxidant molecules 81. Cysteine is the rate-
limiting amino acid in the biosynthesis of glutathione (GSH), a non-protein, tripeptide thiol that 
mediates detoxification of reactive oxygen species (ROS) and redox maintenance82-86. Given the 
high rate of intracellular GSH turnover and the highly reducing intracellular environment 
specifically in KRAS mutant pancreatic cancer cells59, we hypothesized that exogenous cysteine 
sources may play a key role in pancreatic cancer cell biology. 
To test this, we cultured human PDA cell lines in media containing varying 
concentrations of cysteine. In three of four lines (PANC-1, BxPC-3, and AsPC-1), complete 
cysteine withdrawal was uniformly lethal within 24 hours, with PANC-1 cells exhibiting the 
highest sensitivity to de-escalating concentrations of cystine. Early morphological indications of 
these effects were apparent visually by 16 hours (Figure 2-1A, B). Using time-lapse video 




Figure 2-1 Pancreatic cancer cells are sensitive to cysteine withdrawal 
A. Visualization of PANC-1 cells over time by transmitted light. Cells were incubated in media 
containing 200 µM cysteine (+cys), lacking cysteine (-cys), and without cysteine but 
supplemented with 100 µM Trolox,  a water soluble analog of vitamin E, a powerful antioxidant 
(-cys + Tro). 
B. Cysteine dose de-escalation curves in a small panel of pancreatic cancer cell lines (PANC-1, 
BxPC-3, AsPC-1, and MIA PaCa-2). Cells were cultured in increasing amounts of cysteine, 
ranging from no cysteine to 200uM cysteine (curves shown in red), and then this experiment 
was performed in the presence of Trolox at 50uM (curves shown in blue). N=3 biological 
replicates. Error = +/- standard deviation. 
 
plasma membranes, characterized by sudden membrane “ballooning” events, but lacking visual 
evidence of nuclear fragmentation. We hypothesized that due to the key role cysteine plays in 
redox biology, that the cell death in these cells was oxidative in nature. To test this, we 
attempted to rescue the effects of cysteine withdrawal with the antioxidant Trolox. In all sensitive 
lines, Trolox provided a near complete rescue, even in the total absence of cysteine (Figure 2-
1A, B). In contrast, MIA PaCa-2 cells proved resilient to these cell cultures conditions, a 
phenomenon which we will discuss in detail in Chapter 3. The partial loss of relative cell viability 
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observed at the lowest cysteine concentrations was not rescued by Trolox, likely indicating a 
different form of cell death or a cell proliferation defect occurring in these cells. 
Pharmacological inhibition of system xc
- phenocopies the effects of cysteine withdrawal 
 Exogenous cystine enters the cell primarily through the glutamate/cystine antiporter, 
system xc
- 87. To test whether the cell death phenotype induced by cysteine withdrawal could be 
reproduced pharmacologically, we performed dose–escalation viability experiments on the 
same PDA lines using piperazine erastin (PE), a potent analog of the system xc
- inhibitor 
erastin88. PDA cells that exhibited sensitivity to cysteine withdrawal were also highly sensitive to 
system xc
- inhibition (Figure 2-2A, B). Microscopic examination found that sensitive cells died 
beginning at 8 hours after treatment with PE and almost completely by 24 hours. This cell death 
could largely be rescued by co-treatment with Trolox, just as in the case of the cysteine 
withdrawal discussed above. Promoting cystine uptake by the neutral amino acid transporter 
system L through treatment with β-ME89 also rescued these effects. To test that cysteine itself 
could rescue the effects of system xc
- inhibition, ruling out off target effects of our inhibitor, we 
treated cells with both PE and N-acetyl cysteine (NAC), a cell permeable cysteine precursor. 
Results showed that NAC could ably rescue the effects of system xc
- inhibition, confirming 
cysteine itself is mediating the effects of this drug treatment (Figure 2-2C, D). Once again, MIA 
PaCa-2 cells were largely insensitive to these perturbations. Interestingly, the cellular phenotype 
in PANC-1 cells treated with a system xc
- inhibitor was morphological distinct from the apoptosis 
caused by staurosporine (Figure 2-2E). We also noted that among these four lines, there was 
parity between the sensitivity to cysteine depletion and system xc
- inhibition. Taken together, 
these data indicate that pancreatic cancer cells are sensitive to cysteine deprivation, whether 












Figure 2-2 System xc
- inhibition phenocopies the effects of cysteine withdrawal 
A. A. Visualization of PANC-1 cells over time in media containing vehicle (.1% DMSO, veh), 10 µM piperazine erastin 
(PE), and 10uM PE with 100uM Trolox (PE + Tro).  
B. Standard dose response curves in a small battery of pancreatic cancer cells lines ranging from 0 µM PE to 100 µM 
PE (curves in red). Cells were also treated with increasing amounts of PE in combination with 50 µM Trolox (curves in 
blue). Viability was assessed at 24 hours following treatment. N=3 biological replicates. Error = +/- SD. 
C. Cell viability of PANC-1 cells cultured with 10 µM PE in combination with 100 µM Trolox, 50 µM β-ME, or 1mM 
NAC. Error is +/- SD, * = p < .05 by student’s t-test. N = 3 technical replicates. 
D. Dose response curve testing the effects of PE alone or PE in combination with 1 mM NAC on PANC-1 cells. Error 
is +/- SD, n = 3 biological replicates. 




Cysteine deprivation causes ferroptosis in pancreatic cancer cell lines 
 While it was clear from our observations that some PDA cell lines were exquisitely 
sensitive to cysteine withdrawal or system xc
- inhibition, we had not fully interrogated the means 
by which these cells were dying. Rescue with the antioxidant Trolox hinted at a rapid, oxidative 
cell death. This is reminiscent of a form of an iron-dependent, non-apoptotic cell death called 
ferroptosis associated with the accumulation of lipid ROS species 90. To assess whether 
cysteine deprivation induces ferroptosis in sensitive PDA lines, we cultured PANC-1 cells in 
media containing 10 µM PE and attempted to rescue these effects with two canonical inhibitors 
of ferroptosis, Ferrostatin-1 (Fer-1, a lipophilic antioxidant) and deferoxamine (DFO, an iron 
chelator). Microscopically, rescue with fer-1 or DFO restored normal morphology to these cells 
even at 24 hours (Figure 2-3A).  
To quantify these results and rule out other possible forms of cell death, we treated our 
panel of PDA cell lines with media lacking cysteine or containing 10 µM PE and attempted to 
rescue these effects with a variety of cell death inhibitors. Fer-1 and DFO provided the most 
consistent and highest level of rescue in all sensitive lines. By contrast, inhibitors of apoptosis 
(Z-VAD-FMK), necroptosis (Necrostatin-1s), or autophagy (Bafilomycin A1) failed to rescue the 
death of these cells as effectively following cysteine depletion. In the insensitive MIA PaCa-2 
line, no tested agent effectively rescued the effects of cystine withdrawal, consistent with a cell 
proliferation defect rather than a cell death phenotype (Figure 2-3B). Similarly, cells treated with 
a system xc
- inhibitor were rescued most effectively by either fer-1 or DFO. It should be noted 
that when some cells were treated with PE, other agents could provide substantial rescue, 
however. AsPC1 cells, for instance could be rescued with a variety of agents, suggesting that 









Figure 2-3 Cysteine deprivation causes ferroptosis in pancreatic cancer cells 
A. Images of PANC-1 cells treated for 24 hours with vehicle (.2% DMSO), 10 µM PE, 10 µM PE with 500 nM 
ferrostatin-1 (PE + Fer-1), and 10uM PE with 100uM DFO (PE + DFO). Scale bars indicate 50 µM. 
B. Cell viability of pancreatic cancer cells cultured in vehicle (.1% DMSO, veh, shown in gray), the absence of cysteine 
(no cys, shown in red), and in the absence of cysteine but in the presence of 500 nM ferrostatin-1 (Fer-1, shown in 
blue), 10uM Necrostatin 1s (Nec1s, shown in green), 50uM ZVAD-FMK (ZVADFMK, shown in purple), 1nM bafilomycin 
A1 (BA1, shown in orange), and 100uM deferoxamine (DFO, shown in pink). Viability was assessed after 24 hours of 
treatment. Error equals +/- standard deviation. N = 3 biological replicates. * = p<.05 by an unpaired, non-parametric 
student’s t test. x = no significant difference. 
C. Cell viability of PANC-1 and MiaPACA-2 cells cultured in vehicle (.2% DMSO, veh, shown in gray), 5 µM PE (shown 
in red), and the aforementioned compounds and the concentrations indicated in figures G and I. Viability was assessed 
at 24 hours after treatment. Error equals +/- standard deviation. N = 3 biological replicates. * = p<.05 by an unpaired, 
non-parametric student’s t test. x = no significant difference 
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 Another characteristic feature of ferroptosis is the rapid accumulation of lipid ROS in the 
plasma membrane. Using the lipid ROS sensor C-11 Bodipy, we observed a sharp increase in 
lipid oxidation in PANC-1 cells during PE treatment that temporally preceded the onset of cell 
death. This effect was fully rescued by co-treatment with Trolox as quantified by flow cytometric 
analysis (Figure 2-4A). In contrast, plasma membrane ROS accumulation was not induced by 
buthionine sulfoxamine (BSO), a well characterized inhibitor of GSH synthesis 91, a finding we 
will explore in more detail in Chapter 4. These effects were absent from MIA PaCa-2 cells under 
any condition (Figure 2-4A), save treatment with cumene hydroperoxide, a well-known inducer 
of lipid peroxidation92. These results are consistent with the lack of overt cell death in MIA 
PaCa-2 cells that we observed in previous experiments.  
To explore whether the morphological effects we see in sensitive cells are correlated 
directly with lipid ROS accumulation, we visualized both sensitive and insensitive cells under the 
effects of cysteine deprivation (Figure 2-4B). Interestingly, lipid oxidation is present at relatively 
high levels in PANC-1 cells, but not MIA PaCa-2 cells, by 6 hours following either cysteine 
withdrawal or treatment with the system xx
- inhibitor IKE. To quantify these observations, we 
used a flow cytometric approach. PANC-1 cells treated with IKE exhibited a sharp increase in C-
11 Bodipy positivity by 6 hours after treatment (Figure 2-4C). In these samples, up to 72.3% of 
detected cells were positive for the oxidized form of C-11Bodipy. This lipid oxidation 
accumulation could not be alleviated by ZVAD-FMK, Nec1s, or BA1. However, in Fer-1 treated 
samples positivity was reduced to only 14.1%. When we examined the effects of these 
treatments on MIA PaCa-2 cells, we noted no profound increase in C-11 Bodipy positivity. Thus, 
we found that the cell death phenotype induced by cysteine deprivation in PANC1 cells was 
iron-dependent, non-apoptotic, oxidative, and tightly associated with the accumulation of lipid 
ROS. From these collective observations, we conclude that cysteine deprivation in PANC-1 









Figure 2-4 Cysteine deprivation causes a catastrophic accumulation of lipid ROS 
characteristic of ferroptosis 
A. Flow cytometric analysis of PANC-1 and MIA PaCa 2 cells stained with C-11 Bodipy, a marker of lipid 
oxidative stress, after 6 hours of treatment with indicated compounds. Cells were treated with vehicle (.2 
% DMSO, gray); 10 µM PE (red); 10 µM PE and 100 µM Trolox (blue); 600 µM of the GSH-synthesis 
inhibitor buthionine sulfoxamine (BSO, in orange); and 100 µM cumene hydroperoxide, a lipid free-radical 
initiator, (cumene, in green). Representative data from one of three experiments are shown. 
B. Fluorescent visualization of PANC-1 and MIA PaCa 2 cells stained with C-11 Bodipy. Reduced lipids 
are shown in red, oxidized lipids are shown in green, overlayed with a transmitted light image. Cells were 
treated with vehicle (.2% DMSO, veh), incubated in media lacking cysteine (-cys); or treated with 5uM 
IKE, a more potent analog of the system xc- inhibitor erastin (IKE). All images were captured after 6-8 
hours of treatment. 
C. Flow cytometric quantification of PANC-1 and MIA PaCa-2 cells stained with C-11 Bodipy after six 
hours of treatment with 5 µM IKE Positive cells fall into quadrant 3 (Q3). Representative data from one of 





 While research has shown that mutant RAS pancreatic cancer cells create a uniquely 
reducing intracellular environment via Nrf2 upregulation59, research detailing if this biological 
change can be targeted therapeutically is still scant. Recent work has indicated that targeting 
this system in conjunction with the Akt pathway can inhibit pancreatic cancer cell growth93, 
however, it has not yet been shown that targeting a metabolic dependency based on redox 
biology alone can inhibit tumor cell growth. Here we show for the first time that depriving 
pancreatic cancer cells of cysteine, whether directly by exogenous removal from culture media 
or indirectly by pharmacological blockade of system xc
-, can result in abrupt cell death. Other 
cell lines are resistant to cysteine-depleted culture conditions94, highlighting that cysteine 
withdrawal does not represent a universally lethal stress. Interestingly, while previous research 
has shown that various forms of nutrient deprivation can cause cell death by apoptosis or 
regulated necrosis in other cellular contexts95-98, we show that pancreatic cancer cells do not die 
from apoptosis when deprived of cysteine. However, pancreatic cancer cells are not uniformly 
sensitive to this metabolic stress: MIA PaCa-2 cells were not particularly sensitive to the effects 
of cysteine deprivation. This can be interpreted in multiple ways: perhaps these cells create 
cysteine from other sources of sulfur (transsulfuration, catabolism of extracellular proteins); 
upregulate other antioxidant pathways to accommodate cysteine depletion; or these cells simply 
do not produce ROS at a high enough rate to create the accumulation of lipid damage 
necessary to execute the phenotypes we see. This phenomenon will be the subject of more 
extensive inquiry in the next chapter. 
 Cysteine is typically present in the extracellular space as cystine, which is imported 
specifically by system xc
-. Here, we confirm the cystine is the major source of intracellular 
cysteine in standard culture conditions. Importantly, pharmacological blockade of system xc
- 
phenocopies the effects of cysteine withdrawal in sensitive pancreatic cancer cells. This result 
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highlights the inherent druggability of this dependency and bears considerable importance on 
the clinical value of this finding. Previous work has highlighted that system xc
- inhibition can 
cause an iron-dependent, oxidative cell death called ferroptosis99. Here we show that, indeed, 
cysteine deprivation in pancreatic cancer also causes ferroptosis, as evidenced by rescue with 
both ferrostatin-1 and DFO. PANC-1 cells appear to be the most sensitive to the effects of 
cysteine deprivation and also appear to die almost exclusively from ferroptosis in our 
experiments, making them the ideal model cell line to study these effects moving forward. It is 
clear from our work however, that ferroptosis may not account for the only death we see in all 
cell lines. AsPC-1 cells, for example, can be rescued from these stresses quite well when using 
an inhibitor of necroptosis or an inhibitor of autophagy, suggesting interplay between multiple 
avenues of cell death. ZVAD-FMK consistently provides the worse rescue effects across all cell 
lines, underscoring though that apoptosis does not contribute to any appreciable cell death in 
these contexts. Fer-1 and DFO both provide the most reliable rescue in all cell lines, suggesting 
that ferroptosis plays a critical role in mediating the effects in these cells, nonetheless.  
For the first time we show live-cell imaging implicating the accumulation of lipid ROS in 
the potentiation of all of these effects. Consistent with an overall resistance to cysteine 
deprivation, MIA PaCa-2 cells do not accumulate lipid peroxides under these conditions. It is 
important to note, however, that cumene hydroperoxide can create lipid peroxidation in these 
cells, suggesting that they are not simply incapable for the production and propagation of this 
type of damage. Imaging data and time-lapse microscopy showed that the accumulation of lipid 
peroxides and the morphological changes associated with ferroptosis occur in sequence, 
suggesting that lipid peroxides may tightly regulate the effects of cysteine deprivation, 
consistent with previous reports100-103. In these experiments, we also tested a known inhibitor of 
GSH synthesis, buthionine sulfoxamine (BSO), since we hypothesized that GSH depletion 
mediated the accumulation of lipid peroxides, based on previous work88. Surprisingly, there was 
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no evidence that BSO could cause the same accumulation of lipid damage over the equivalent 
time span. These results prompts questions regarding the precise role that cysteine, GSH, and 
other cysteine derivatives actually play in ferroptosis in these cells, forming the basis for inquiry 


























Chapter 3 - Macropinocytosis, but not transsulfuration, mediates insensitivity to the 
effects of system xc












Background and Significance 
 In a clinical setting, cancers do not respond equally well to all treatment regimens. In 
fact, one of the major goals of modern precision medicine is to determine, whether by genomic 
profiling or master-regulator analyses, what drugs will work most effectively in a given patient. 
As such, modelling variable drug response in cancer may prove important in foreseeing possible 
modes of resistance to a proposed means of treatment. In our previous experiments, we found 
that three out of four pancreatic cancer cell lines tested were sensitive to cysteine depletion via 
ferroptotic cell death. However, Mia PACA-2 cells exhibited a priori insensitivity to this nutrient 
deprivation. We thought it valuable to study the biology of cells which were insensitive to 
cysteine deprivation as a means to model the biology of tumor that may not respond to system 
xc
- inhibition.  
 We hypothesized that Mia PACA-2 cells were not in fact resistant to cysteine deprivation 
per se, but instead able to acquire cysteine by alternative means.  In addition to importing 
cystine, cells can synthesize cysteine by transferring the sulfhydryl group of methionine to the 
carbon backbone of serine using the transsulfuration pathway104-108. Previous work has 
highlighted that induction of the transsulfuration pathway can inhibit ferroptosis induced by 
cysteine deprivation109, making this an attractive pathway to interrogate in MIA PaCa-2 cells. 
Cysteine could also be acquired through the uptake of exogenous materials via vesicle-
mediated processes such as macropinocytosis. Protein uptake via macropinocytosis has been 
shown to provide amino acids in RAS–driven cancers, and inhibition of this process 
compromises the growth of pancreatic tumor xenografts 48. In this chapter, we explore the 
hypotheses that these pathways confer resistance to ferroptosis in MIA PaCa-2 cells. 
Results 
Cysteine biosynthesis through transsulfuration provides a minor component of total 
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cysteine levels in pancreatic cancer cells 
To interrogate if transsulfuration plays a critical role in providing free cysteine to 
pancreatic cancer cells, we undertook a series of labeling experiments to track the movement of 
carbons donated by methionine to other metabolites (Figure 3-1). Transsulfuration begins with 
methionine, which is enzymatically converted to S-adenosylmethioine (SAM) by methionine 
adenosyl transferase. Various methyl transferases may act on SAM to yield S-
Adenosylhomocysteine (SAH). SAH is converted into homocysteine by a specific hydrolase. 
Homocysteine then goes on to one of two fates: it can be converted back into methionine by the 
enzyme methionine synthase, or it can be converted to cystathionine by the addition of a serine 
as catalyzed by cystathionine β-synthase (CBS). To complete the production of cysteine, 
cystathionine γ-lyase (CGL) decomposes cystathionine into cysteine, producing an ammonium 
ion and α-ketobutyrate. In our experiment, we cultured PANC-1 and MIA PaCa-2 cells in 
medium containing methionine synthesized with isotopically-labeled carbon (13C). In this 
experiment, cells were treated concomitantly with labeled substrate and various compounds. 
Metabolites were extracted and then subject to mass spectrometry-based profiling to analyze 
13C-label incorporation into components of the transsulfuration pathway. In both cell lines we 
found that nearly 50% of the cystathionine pool was labeled with 13C after 6 hours, and this 
reached 90% by 24 hours. At no point did we detect labeled α-ketobutyrate. Of note, pathway 
labeling was not altered by treatment with either BSO or PE, suggesting that neither cell line 
modulates activity of this pathway in response to cysteine deprivation or GSH depletion. 
Furthermore, metabolite abundance of transsulfuration intermediates did not change in either 
sensitive or insensitive cells upon treatment with BSO or PE (Figure 3-2A, B).  
To test if long-term incorporation of labeled methionine could be perturbed in the context 
of system xc
- inhibition, we performed a second labeling experiment in which cells were 





Figure 3-1 The transsulfuration pathway 
Detailed above are key steps in the transsulfuration pathway, which in mammals catalyzes the 
biosynthesis of cysteine from methionine. In the described labeling experiment, 13C labeled carbon is used 
to synthesize methionine, which can then be tracked by mass spectrometry. Metabolites that derive some 
subset of their carbon skeleton from carbons in methionine are indicated in red typeface. Enzymes that 
catalyze these reactions are boxed in blue.  
Abbreviations: MAT, methyl adenosyl transferase; MT, methy transferase; SAHH, S-adenosyl 






Figure 3-2 Neither system xc
- inhibition nor GSH synthesis impairment cause increase flux through 
the transsulfuration pathway 
Measurements of incorporation of 13C-labeled methionine into transsulfuration intermediates. Cells were 
pretreated for 16 hours with labeled substrate and then treated with vehicle (.05% DMSO, shown gray) or 5 
µM PE (shown in red), for six hours. N = 3 biological replicates. Error = +/- SD. Of note, alpha-ketobutyrate 
is unlabeled in all treatments, showing that the final step of transsulfuration is not active in these cells 
under any of the treatment conditions. 
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entire pool of transsulfuration intermediates to be labeled prior to metabolic stress. Structured 
this way, the experiment would allow us to detect steady state levels of transsulfuration 
products. Examining the percent of total metabolite pools labeled, we detect nearly complete 
labeling of all transsulfuration intermediates in both vehicle and PE treated samples in both cell 
lines. In contrast, α-KB labeling was not detected in either PANC-1 or MIA PaCa-2 cells under 
either treatment condition, which may reflect low flux through the final step of the 
transsulfuration pathway (Figure 3-3A, see Figure 3-1). To complement these biochemical 
data, we assessed whether transsulfuration pathway activity functionally affects the sensitivity of 
PDA cells to cysteine depletion. MIA PaCa-2 cells were treated with propargylglycine (PPG), 
which inhibits cystathionase (CGL), the enzyme which catalyzes the final step of 
transsulfuration110. PPG alone did not alter cell viability, even at high concentrations (Figure 3-
3B). Moreover, co-treatment of PE at varying concentrations with 1mM PPG did not alter the 
sensitivity of MiaPACA-2 cells to PE–induced cell death (Figure 3-3C). These data are 
consistent with the results of the 13C-methionine labeling experiment above that indicate 
transsulfuration pathway activity is not altered by PE treatment within 6 hours. From these 
collective experiments, we conclude that the transsulfuration pathway does not contribute 
appreciably to cysteine pools in these PDA cell lines and is not a major determinant of 
sensitivity to cysteine depletion in this context. 
Macropinocytosis is upregulated in MIA PaCA -2 cells, but not PANC-1 cells, in response 
to system xc
- inhibition 
Cysteine could also be acquired through the uptake of exogenous materials via vesicle-
mediated processes such as macropinocytosis. Protein uptake via macropinocytosis has been 
shown to provide amino acids in RAS–driven cancers, and inhibition of this process 
compromises the growth of pancreatic tumor xenografts 48. To test whether macropinocytosis 




Figure 3-3 Transsulfuration does not mediate sensitivity of pancreatic cancer cells to cysteine 
deprivation 
A. PANC-1 and MIA PaCa-2 cells were cultured with 13C labeled methionine for 16 hours and then treated 
with either vehicle (.1% DMSO, in gray), or with 10 µM PE (in red) for 6 hours. Metabolites were then 
extracted and subject to analysis by mass spectrometry. No significant changes in labeling were identified 
in the metabolites shown here, and notably, no labeling was detected in α-KB. N = 3 biological replicates. 
Error = +/- SD. 
B. Dose response of propargyglycine (PPG), a transsulfuration inhibitor, in MIA PaCa-2 cells.  Cells were 
treated for 24 hours. N = 3 technical replicates. Error = +/- SD. 
C. Dose response of PE alone, or in combination with 1 mM PPG for 24 hours in MIA PaCa-2 cells. Cells 
were treated for 24 hours. N = 3 biological replicates. Error = +/- SD. 
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 and MIA PaCa-2 cells by measuring uptake of a high molecular weight fluorescently labeled 
dextran, as described previously111. Using high magnification fluorescent microscopy, we noted 
that healthy PANC-1 cells in their logarithmic growth phase did not form macropinosomes to any 
appreciable extent (Figure 3-4A, B). Notably, MIA PaCa-2 cells, which were insensitive to 
cysteine deprivation, showed high macropinocytotic activity in vehicle treated samples. In the 
MIA PaCa-2 cells, dextran uptake was further increased by co-treatment with PE, and was fully 
blocked by the macropinocytosis inhibitor ethylisopropylamiloride (EIPA)112 (Figure 3-4C, D). 
These results suggest that macropinocytosis is upregulated in direct response to metabolic 
stress, a means to acquire the biomolecular substrates required for survival in these conditions. 
Macropinocytosis mediates sensitivity to system xc
- inhibition in MIA PaCa-2 cells 
 Next we examined the impact of macropinocytosis inhibition on the cell viability of MIA 
PaCa-2 cells following system xc
- inhibition. Whereas treatment of these cells with PE at 
increasing concentrations had no effect on viability, the addition of EIPA led to near-complete 
sensitization to system xc
- inhibition (Figure 3-5A). The loss of viability was almost completely 
rescued by NAC and Trolox, similar to results seen in PANC-1 cells treated with PE alone, as 
previously discussed (See Figure 2-2C). To confirm that EIPA alone was not dictating these 
effects, we carried out a cell viability assay, treating MIA PaCa-2 cells with an array of 
compounds to attempt to rescue these effects, which we hypothesized were mediated by 
ferroptosis, as in previous examples. While neither PE nor EIPA alone killed MIA PaCa-2 cells, 
the combination of these drugs managed to achieve nearly complete cell killing. These effects 
were rescued at least partially by co-treatment with β-mercaptoethanol (β-ME), a potent 
reducing agent; DFO; Fer-1; and NAC, providing strong evidence that these otherwise–resistant 
cells are dying at least partially of ferroptosis following a combination system xc
- and 
macropinocytosis inhibition (Figure 3-5B). We therefore conclude that macropinocytosis 




Figure 3-4 MIA PaCa-2 cells, but not PANC-1 cells, upregulate macropinosome formation in 
response to system xc
- inhibition 
A, B. Fluorescent microscopic visualization of PANC-1 and MIA PaCa-2 cells treated for six hours with 
vehicle (.5 % DMSO); 10 µM PE; 50 µM EIPA, an inhibitor of micropinocytosis; and with PE and EIPA in 
combination.  
C, D. Quantification of fluorescence microscopy data presented above. The average number of 
macropinosomes per cell was counted for 10 randomly selected fields per condition to calculate average 
macropinoctytotic index.  Error bars indicate mean +/- S.D, with N=3 biological replicates. * = p<.05, 






In Chapter 2, we determined that a subset of pancreatic cancer cell lines were 
exquisitely sensitive to cysteine deprivation. Notably, one cell line, MIA PaCa-2, exhibited 
almost no ill effects from these perturbations within 24 hours. In efforts to model potential 
Figure 3-5 Inhibiting macropinocytosis sensitizes previous unaffected pancreatic cancer cells to 
system xc
- inhibition 
A. Cell viability assessment of MIA PaCa-2 cells treated with vehicle (.5% DMSO), varying concentrations 
of PE alone; PE in combination with 50 µM EIPA; PE, EIPA and 1 mM N-acetyl cysteine (NAC), a cell 
membrane permeable analog of cysteine; and PE, EIPA, and 100 µM Trolox, a lipohilic antioxidant. Each 
condition was normalized to its respective vehicle. Error bars indicate +/- SD, N=3 biological replicates. 
Statistical significance was determined via two-way ANOVA then Tukey’s multiple comparisons test; 
*p<0.0001. All measurements were taken at 24 hours post initiation of treatment. 
B. Cell viability assessment of MIA PaCa-2 cells treated for 24 hours with vehicle (0.5% DMSO), PE (15 
μM), EIPA (50 μM), Trolox (100 μM), BME (100 μM), DFO (100 μM), Fer-1 (500 nM), and NAC (500 μM), 
or as indicated. Error bars indicate +/- SD, N=3 technical replicates. Statistical significance was determined 





mediators of sensitivity to cysteine deprivation and thereby ferroptotic cell death in a cancer 
context, we utilized the marked differences in PANC1 and MIA PaCa-2 cells to execute the 
experiments discussed herein. Previous research had shown that transsulfuration was a 
potential mediator of resistance to ferroptosis in the context of cysteine deprivation109, providing 
an attractive candidate to test in our experimental paradigm. Using a methionine-based labeling 
approach, we assessed flux through the transsulfuration pathway in our two model cell lines. 
Interestingly, transsulfuration intermediates were in fact produced in these cells in vehicle 
samples, proving that at least portions of the pathway are active under normal conditions. 
Fascinatingly, we failed to detect labeled αKB in either cell line under any conditions, which is 
consistent with a model in which pancreatic cancer cells actively create cystathionine but fail to 
catalyze the final reaction in the transsulfuration pathway. It is possible that we did not detect 
αKB because this metabolite is produced but is quickly and regularly transported out of the cell, 
but results in which we use PPG (a transsulfuration inhibitor) and a system xc
- inhibitor in 
combination fail to produce any synergistic effects, consistent with limited pathway activity. This 
leaves us with the much more likely model that cysteine is simply not biosynthesized at the level 
required to confer resistance to either PANC-1 cells or MIA PaCa-2 cells, suggesting that any 
resistances to system xc
- inhibition in pancreatic cancer are not likely to be overcome by 
transsulfuration inhibition.  
Macropinocytosis is a well-studied endocytic process that has been linked to the 
expression of oncogenes, including mutant RAS113. In pancreatic cancer specifically, it has been 
identified as an alternate route by which amino acids can be acquired through bulk uptake of 
extracellular contents48.  In that study, the model cell lines chosen to explore these effects were 
in fact MIA PaCa-2 cells and BxPC3 cells, wherein MIA PaCa2-cells exhibited high levels of 
macropinocytosis. Here, we recapitulate that finding, and show for the first time that PANC-1 
cells do not produce macropinosomes at appreciable numbers. We also show for the first time 
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that otherwise resilient cells can be sensitized to ferroptosis by way of cysteine deprivation by 
inhibiting macropinocytosis. These data support the possibility of using macropinocytotic index 
as a biomarker of potential sensitivity to both cysteine deprivation and ferroptosis, but more 
research is warranted in this vein to confirm this prospect. From a clinical perspective, this 
research is important because it models the possible outcomes of system xc
- inhibition in a 
patient setting. One of the major goals of precision medicine is to define subset of patients 
populations that will respond best to a given treatment regimen. Put more simply: to find the 
right treatment for the right patients. Here, we model a possible mechanism by which cells can 
avoid the effects of system xc
- inhibition and provide a solution to overcome this resistance. 
There are no doubt other mechanisms by which cells can avoid the ill effects of nutrient 
deprivation, and more work to highlight these potential mechanisms will serve us well as we 





















Chapter 4 – Cysteine, GSH, and their roles in mediating ferroptosis  











Background and Significance 
 We have shown that pancreatic cancer cells are sensitive to cysteine deprivation and 
even those that are insensitive can be induced to undergo a similar mechanism of cell death 
under those conditions (ferroptosis), provided we inhibit other modes of cysteine acquisition 
(macropinocytosis). The prevailing mechanism for how cysteine depletion may lead to 
ferroptosis is based on its role as the rate-limiting precursor for glutathione (GSH) 88,114. GSH 
itself can directly react with ROS, or it may be used as a cofactor by enzymes that catalyze the 
detoxification of particular ROS. One example of such an enzyme is glutathione peroxidase 4 
(GPX4), which is the only known lipid peroxidase in mammals115,116. To date, ferroptosis–
inducing compounds have been found either to inhibit system xc
- or GPX4, which has led to a 
model in which depletion of glutathione pools by system xc
- inhibition leads to inactivation of 
GPX4, causing the catastrophic accumulation of lipid ROS that are responsible for killing these 
cells. 
 Because GSH levels correlate with response to cytotoxic treatment117,118, limiting its 
production has been the subject of clinical inquiry for over 50 years. BSO has been found to 
profoundly deplete intracellular stores of GSH in patient tumor samples, but has not been tested 
as a monotherapy119. Early clinical trial work focused on the combination of BSO with the 
alkylating agent L-PAM (melphalan), but adverse toxicity profiles  and limited in vivo efficacy 
may limit the potential of this dual-combinatorial approach to sensitizing tumors to 
chemotherapy120. In previous experiments, we noted that the GSH-synthesis inhibitor BSO 
failed to recapitulate some of the phenotypic responses of pancreatic cancer cells to cysteine 
deprivation (Figure 2-4A).However, we had not formally tested the effects of BSO treatment 
over longer periods nor had we definitively shown that GSH levels in these cells were 
completely ablated by BSO treatment. In efforts to more thoroughly characterize the roles of 
cysteine, GSH, and other possible cysteine derivatives in causing ferroptosis in PDA cells, we 
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describe in this chapter a series of experiments that show for the first time that GSH depletion is 
necessary, but not sufficient to cause the deleterious effects of cysteine deprivation in PDA cell 
lines. Furthermore, using a cysteine-labeling approach analogous to the system described for 
methionine-tracing in Chapter 3, we attempt to delineate key differences between cells that 
have been treated with a GSH-depleting agent versus cells that have been wholly deprived of 
cysteine. We implicate other cysteine derivatives required for the de novo synthesis of 
undamaged lipids or for the production of lipophilic antioxidants as a necessary component of 
engaging ferroptotic cell death in these cells, refining the current model of ferroptotic cell death. 
Results 
GSH depletion is necessary, but not sufficient to cause ferroptotic cell death in PANC-1 
cells 
To test if GSH depletion is necessary for the cell death effects we see in PDA cells, we 
attempted to rescue cells deprived of cysteine by the addition of a cell permeable form of GSH, 
GSH-ethyl ester (GSH-EE)121. We found that high millimolar concentrations of GSH-EE were 
able to provide complete rescue from culture conditions absent of cysteine in PANC-1 cells 
(Figure 4-1A), consistent with research showing that intracellular concentrations of GSH can 
range from 1-10 mM122. PANC-1 cells treated with a system xc
- inhibitor were similarly able to be 
rescued with GSH-EE (Figure 4-1B). Therefore, providing the cell with exogenous GSH-EE is 
sufficient to rescue PDA cells from ferroptosis. To confirm that system xc
- inhibition did in fact 
deplete GSH levels in these cells, we used a mass spectrometric platform to assess the levels 
of intracellular GSH directly. Consistent with a model in which GSH depletion is critical for 
ferroptosis, we see that both GSH and GSSG (oxidized GSH) levels drop precipitously in 
PANC-1 cells (Figure 4-1C).  To get a clearer picture of the redox state of these cells, we next 
calculated the ratio of GSH:GSSG, a marker of oxidative stress and overall cell health123-126. As 
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expected, GSH:GSSG ratio dropped very low in PANC-1 cells, confirming the compromised 
capacity of these cells to maintain proper redox balance under the constraints of cysteine 
deprivation. Interestingly, we were not able to measure any significant drop in GSH, GSSG, or 
GSH:GSSG levels in MIA PaCa-2 cells, consistent with their overall insensitivity to system xc
- 
inhibition (Figure 4-1D). Taken together, these data suggest that GSH depletion is necessary to 
achieve ferroptotic cell death in PDA cells. 
Figure 4-1 GSH depletion is required for ferroptotic cell death 
A, B. Rescue of the effects of growing PANC-1 cells in the absence of cysteine or when treated 
with the system xc
- inhibitor PE by supplementing with GSH-ethyl esther (GSH-EE). N = 3 
biological replicates. Error bars +/- SD. * = p < .05 by t test. Measurements are taken 24 hours 
after treatment initiation. 
C, D. The effects of system xc- inhibition on the depletion of intracellular GSH, oxidized GSH 
(GSSG), and the ratio of these two molecules in both PANC-1 and Mia-PACA2 cells, as measured 
by mass spectrometry. Analytes were extracted and processed 6 hours after treatment initiation. N 
= 3 biological replicates, error bars +/- SD. * = p < .05 by t test 
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 Another prediction of the model above is that glutathione depletion alone may be 
sufficient to induce ferroptosis. We therefore evaluated the effects of GSH depletion on PDA cell 
viability using buthionine sulfoxamine (BSO), an inhibitor of gamma-glutamylcysteine 
synthetase, the penultimate step of GSH synthesis127. Using mass spectrometry, we affirmed 
that BSO effectively depleted both reduced and oxidized glutathione (GSH and GSSG, 
respectively) from PANC-1 cells, leading to near-complete loss of GSH pools over 24 hours. 
(Figure 4-2A).Contrastingly, MIA PaCa-2 cells exhibited slightly differently GSH depletion rates. 
While initial abundance of GSH was comparable across the two lines, BSO also managed to 
deplete intracellular GSH, as expected, albeit at a slightly slower rate when compared to PANC-
1 cells. (Figure 4-2B). However, in stark contrast to cysteine deprivation, GSH depletion had no 
effect on cell viability at 24 hours (Figure 4-2C). We conclude from these results that GSH 
depletion is necessary, but not sufficient, for the induction of ferroptosis following cysteine 
depletion. 
Exogenous cysteine is incorporated into acetyl CoA pools and CoA byproducts can 
rescue cell death caused by cysteine deprivation 
 We infer from the findings above that, in concert with GSH depletion, the loss of one or 
more additional cysteine-derived functions or metabolites contributes to the induction of 
ferroptosis. In mammals, cysteine is utilized in a limited number of reactions (Figure 4-3). 
Outside of GSH, additional products of these reactions include proteins (via translation), taurine 
and pyruvate production (via cysteine sulfinate production), and Coenzyme A (CoA, via the 
pantothenate pathway).  We reasoned that the timescale over which ferroptosis induction 
occurs (~8 hours) following cysteine deprivation is not consistent with an effect on protein 
translation, which would take a much longer time to affect protein pools and cell viability128. In a 
manner akin to the 13C- methionine labeling experiment described in Chapter 3, we analyzed 
metabolite fractions by LC-MS based metabolomics from 13C-labeled cystine samples. Here, 
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we found that labeling of taurine, lactate, glutamate, and citrate were negligible (i.e. below level 
of detection) after 24 hours (Figure 4-4). Pyruvate is not readily detectable by LC-MS. As such, 
metabolites derived from pyruvate in the cytosol (i.e. lactate) or mitochondria (i.e. citrate and 
glutamate) were analyzed. These results suggest that neither taurine biosynthesis nor 
cysteine’s contribution to pyruvate synthesis and the production of TCA cycle intermediates is 
minor. 
Figure 4-2 GSH depletion is not sufficient to case ferroptotic cell death 
A, B. Mass spectrometric measurements of intracellular pools of GSH in PANC-1 and MIA PaCa-2 
cells treated with vehicle (.2% DMSO) or 600 µM BSO Cells were processed at 6 hours or 24 
hours post treatment initiation. N=3 biological replicates, errors bars +/- SD. 
C. The effects of a dose escalation of BSO on PANC-1 and MIA PaCa-2 cells’ viability. N = 3 





Figure 4-3 Cysteine and its biomolecular products 
Pictured above is a working model of cysteine and its various biomolecular roles in the cell. It is 
critical for protein synthesis, some portion of pyruvate production, taurine biosynthesis, the 
production of Coenzyme A, and the synthesis of GSH. Isotopically labeled carbons are highlighted in 
red, while enzymes are boxed in blue. 
Abbreviations: HDH, hypotaurine dehydrogenase; CSAD, sulfinoalanine decarboxylase; CDO, 





 Given these results, we focused our investigation on Coeznyme A (CoA) and its 
derivatives. Indeed, under basal conditions in both PANC-1 and MIA PaCa-2 cells, fully 50% of 
cellular CoA becomes labeled over the course of 24 hours in baseline conditions, indicating a 
steady contribution of exogenous cysteine to CoA pools (Figure 4-5A).CoA is an essential 
substrate for the de novo synthesis of fatty acids, sterols, and the production of lipophilic 
antioxidants, all of which could play a critical role in alleviating the toxic effects of lipid damage 
that we see in pancreatic cancer cells deprived of cysteine. To explore if known fatty acid 
antioxidants downstream of CoA synthesis could abrogate the effects of system xc
-- treated 
samples, we attempted rescue experiments using idebenone, a cell permeable form of 
coenzyme Q10, a product of the mevalonate pathway which utilizes CoA as a primary carbon 
source. The results indicated the system xc
- inhibition could be completely rescued by 
Figure 4-4 Cysteine does not enter the cysteine sulfinate production branch of cysteine 
metabolism in pancreatic cancer cells 
The measurement of 13C-labeled cysteine products in a variety of treatment settings. PANC-1 and 
MIA PaCa-2 cells were treated with vehicle (.05% DMSO, in gray and dark gray), 5 µM IKE (in red), 
or 600 µM BSO (in gold and dark gold) for indicated time points.  No labeled metabolites were 
detected in this experiment under any condition. 
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idebenone across all tested concentrations (Figure 4-5B). The rescue was even more 
pronounced than that achieved by Trolox in previous experiments. 
  
Figure 4-5 Cysteine as incorporated into CoA pools and CoA products can rescue ferroptosis 
A. The incorporation of C13 labeled cysteine into intracellular CoA pools as measure by mass 
spectrometry. Cells were treated with vehicle (.5% DMSO) for indicated times prior to sample 
collection. 
B. Dose response curves of PANC-1 cells treated with IKE (red curve), IKE and 100 µM Trolox (blue 
curve), and IKE and 10 µM idebenone (light blue curve) for 24 hours. 
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Lipid synthesis is another possible means to overcome lipid ROS damage. Consistent 
with the idea that de novo lipid synthesis itself is critical to mediate ferroptotic cell death, we see 
in PANC-1 cells that palmitate is among the top metabolites depleted in IKE when compared to 
BSO treated samples (Figure 4-6). Interestingly, this trend is reversed in MIA PaCa-2 cells, 
consistent with the evidence that these cells acquire cysteine by other means and use it to 
create essential cysteine-based metabolites to avoid ferroptosis (Figure 4-7). Taken together, 
our labeling data suggests the cysteine deprivation caused by system xc
- inhibition causes 
unique metabolic dysfunctions when compared to the blockade of GSH synthesis by BSO. 
Interestingly, some of the most clear metabolite differences exist with regards to lipid production 
and CoA biosynthesis, consistent with a model that stipulates that both GSH and other cysteine-
derived materials are critical for averting ferroptosis in pancreatic cancer cells. 
Discussion 
 Current models of ferroptosis center on the depletion of GSH and its subsequent effect 
on GPX4 function. GPX4 uses GSH as a cofactor to specifically detoxify lipid ROS, believed to 
be the harbingers of ferroptotic cell death. Here, we show for the first time that GSH depletion, 
while necessary for pancreatic cancer cells to undergo ferroptosis, is not sufficient to cause this 
phenotype in these cells. Clearly, sensitive PANC-1 cells exhibit a sharp decline in intracellular 
GSH stores when treated with a system xc
- inhibitor, whereas insensitive MIA PaCa-2 cells do 
not. We initially hypothesized that direct GSH depletion would circumvent any differences in 
sensitivity since it targeted antioxidant systems much more downstream than cysteine 
deprivation. To our surprise, however, BSO treatment accomplished its pharmacological goal 
without causing any ill effects. Interestingly, other research has shown that GSH is actually 
required for cancer initiation, but once tumors are established, they upregulate other antioxidant 
production to dispense with their reliance on GSH synthesis79. In this work, the authors 




























































































































































































































































































































































































































































































































































with BSO and auranofin, respectively, could reduce tumor growth in a xenograft model of breast 
cancer. In a similar vein, our work suggests that BSO alone is not enough to cause deleterious 
phenotypes in cancer cells. 
 These findings prompted us to interrogate further what the precise roles of cysteine and 
GSH are in these cells. Using a 13C-labeling approach, we tracked the movement of cysteine 
carbons throughout various metabolic systems to get hints as to what functions of cysteine, in 
addition to its role in GSH synthesis, may be critical to maintaining low levels of lipid ROS. 
Cysteine’s role in the production of bioenergetic TCA intermediates does not seem to be critical 
in these cells, since we see little to no labeling pyruvate products in either PANC-1 or MIA 
PaCa-2 cells. We rule out taurine biosynthesis as the prime cysteine product responsible for 
these differences due to the lack of labeled taurine production under any of our experimental 
conditions. We were left to explore either protein production or the critical role of cysteine in 
CoA synthesis. Cyclohexamide can be used to inhibit protein synthesis129, but we reasoned that 
given its cytotoxicity profile, testing this compound in combination with BSO would not yield a 
potential therapeutic regimen. Furthermore, the median half-life of eukaryotic proteins is 46 
hours130, making it unlikely that the effects we see are caused by some deficiency in protein 
synthesis caused by cysteine deprivation.  
Instead, we focused our efforts on CoA, a notable coenzyme critical for the production of 
fatty acids and fatty acid oxidation. We show for the first time that cysteine is relatively quickly 
incorporated into CoA pools, showing hints of incorporation by 6 hours and over 50% 
incorporation by 24 hours, at baseline conditions, in either PANC1- or MIA PaCa-2 cells.  CoA is 
a critical substrate for the mevalonate pathway, which is responsible for the production of 
isoprenoids, like cholesterol and coenzyme Q. Coenzyme Q is a lipophilic antioxidant and we 
show that a derivative of this molecule, idebenone, can rescue ferroptosis, consistent with 
previous reports131. These data suggest that other antioxidants of the cell can surmount the 
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effects of GSH depletion but only in the presence of adequate cysteine, though more research 
remains to be done to highlight the precise role that the mevalonate pathway and its derivatives 
may play in protecting cells from ferroptosis. 
Finally, we used a non-biased metabolite screening approach to characterize major 
differences between cells treated with a cysteine depleting agent versus a GSH depleting agent. 
Here, we note that a key component of this signature associated with IKE treatment in PANC-1 
cells is the depletion of DNA base precursors (cytidine diphosphate, guanosine diphosphate, 
adenosine, adenosine monophosphate). We suspect this is a byproduct of the unhealthful state 
of IKE-treated PANC-1 cells, but have not formally tested this. Instead, we highlight that 
palmitate, the first fatty acid produced in fatty acid synthesis, is actually one of the most 
differentially downregulated metabolites in PANC-1 cells treated with BSO versus IKE by 6 
hours. We hypothesize that this is due to compromised fatty acid synthesis as a result of 
cysteine depletion, which limits production of CoA , acetyl-CoA and thereby production of 



















Chapter 5 – SLC7A11 expression in human tumors and the effect of its deletion on 












Background and Significance 
 While modeling human cancer biology in cell culture systems is an important tool for 
studying the mechanistic underpinnings of a given effect in a well-controlled setting, most agree 
that a thorough preclinical evaluation of the potential value of targeting a specific biological 
system requires relevant human data and in vivo modeling. Heretofore, our work has focused 
on carefully characterizing the effects of cysteine deprivation, both directly and 
pharmacologically, on pancreatic cancer cells in culture. In efforts to determine if cystine 
transport might be relevant in more clinically translatable settings, we explored the expression of 
SLC7A11, the specific subunit of the system xc
- transporter, in human tumors, and generate an 
entirely new, genetically engineered mouse model to study the effects of SLC7A11 deletion on 
established pancreatic tumors. 
 While there is some work to suggest that SLC7A11 is overexpressed in human 
cancers132,133, a thorough analysis of publicly available, large-scale data sets containing 
comprehensive RNAseq data has not been carried out. In this chapter, we detail our work 
characterizing mRNA expression levels of SLC7A11 on an in-house RNA-seq data set derived 
from laser-captured, microdissected human PDA samples. We also show for the first time that 
SLC7A11 is overexpressed in pancreatic cancers compared to bulk normal pancreatic tissue in 
multiple, independent data sets. We also show for the first time that this gene is overexpressed 
in a multitude of other human cancers, suggesting that some of the findings detailed in this work 
may have broader applicability. Furthermore, we report that mutant KRAS expression correlates 
positively with the expression of this transcript in human cancers, corroborating previous studies 
suggesting that mutant KRAS can directly control expression of SLC7A11. Finally, we detail 
novel data correlating SLC7A11 with poor prognosis in multiple cancer types.  Together, these 
data imply that SLC7A11 may in fact play a vital role in human cancer biology and support our 
argument that it may be a valuable new pharmacological target in pancreatic cancer.  
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 While the human data present in the chapter present a compelling correlational case for 
the importance of SLC7A11 in tumor development, no research has yet been done to show that 
targeting this transporter in a mouse model of pancreatic cancer can have beneficial effects. 
Genetically engineered mouse models of cancer, in which careful, genetic control of 
endogenous alleles is leveraged to promote tissue-specific tumor formation, provide the most 
validated model of cancer that we currently have available134,135. In efforts to more fully 
understand the importance of cystine import in vivo, we undertook a three-year long breeding 
protocol to produce a genetically engineered mouse model (GEMM) of PDA in which we can 
also control global deletion of other genes via a dual recombinase system, building on previous 
modelling strategies136. This is the first report of a dual-recombinase GEMM based on the 
biology of the KPC model64. In the latter half of this chapter, we report that global deletion of 
exon three of Slc7a11 (the mouse homolog of SLC7A11) in the context of established 
pancreatic tumors can slow their growth and extend overall survival. These benefits seem to be 
conferred due to the increased oxidative burden on these tumors, as suggested by the 
abrogation of this effect in mice co-treated with NAC. Taken together, these results make a 
compelling case that cystine import is critical for pancreatic tumor growth in vivo and presents a 
novel therapeutic avenue in pancreatic cancer. 
Results 
SLC7A11 is overexpressed in human tumor tissue and overexpression correlates with 
poorer outcomes 
System xc
- is comprised of two protein subunits, SLC3A2 and SLC7A11. While SLC3A2 
is a member of many amino acid transporters, SLC7A11 is specific to system xc
-. To study the 
potential clinical relevance of our previously reported findings, we examined mRNA expression 
of SLC7A11 in human cancer. One confounding factor in the analysis of gene expression from 
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bulk PDA samples is the presence of large amounts of stromal or infiltrating–normal cells within 
the tumor mass. Our group recently performed laser capture microdissection and RNA–
sequencing on a large cohort of human pancreatic tumors, deriving a stromal and an epithelial 
profile for each. To analyze SLC7A11 expression, we first determined the distribution of this 
gene’s expression in all de-identified samples. This distribution yielded a normalized expression 
plot centered on 0 and with a standard deviation of 1. We then replotted these data, separating 
the distributions for epithelial samples versus stromal samples plotted on the same scale. These 
results revealed that SLC7A11 was overexpressed in malignant epithelial tissue as compared to 
stromal samples (Figure 5-1A). We extended our analysis of malignant tissue to test if there 
were any expression differences in SLC7A11 between preneoplastic lesions versus established 
primary tumors. Here, we found that increasing expression was associated with primary tumors 
when compared to PanINs (Figure 5-1B), suggesting that SLC7A11 expression increases may 
be a late occurrence in tumor development.  All of these data, however, represent only one 
cohort of patients from one institution. To make our analyses more thorough, we then examined 
six published reports of PDA gene expression data that included matched normal tissues. 
Notably, SLC7A11 expression was significantly increased over normal in four of the six 
datasets. Effects sizes varied from 1.33 to 2.38 fold change, while a meta-analysis of all data 
sets corroborated these results (Figure 5-1C). Taken together, these data show for the first time 
that SLC7A11 is overexpressed in human PDA compared to normal pancreatic tissue. 
Next, we extended our research question to a broader cohort of cancer types to test the 
widespread applicability of this finding. When we examined SLC7A11 expression in the TCGA 
data set for a variety of cancers, we found multiple cancer types showed significant upregulation 
of this transcript (Figure 5-2A), suggesting the importance of this transporter in pancreatic 
cancer may be extrapolated to many cancer types. We sought to explore the correlation of 




Figure 5-1 SLC7A11 transcript is overexpressed in human pancreatic cancer 
A, B. LCM RNA-Seq from matched human PDA epithelium and stroma shows epithelial expression 
of SLC7A11. When we examine early lesions (PanINs) and late PDA, we note that expression of 
SLC7A11 is enriched in fully developed cancer. 
C. A meta-analysis showing that SLC7A11 is overexpressed in primary PDA tumors as compared to 
normal control tissue in of multiple pancreatic cancer data sets (right panel). Left panel shows effect 
size estimates with their 95% confidence interval per study as well as meta-analytic summaries 





TCGA data set for which there was a significant difference in SLC7A11 expression, we find that 
high SLC7A11 expression is consistently correlated with a poorer survival outcome (Figure 5-
2B). 
Figure 5-2 SLC7A11 is overexpressed in many human cancers and can correlate with poor 
survival 
A. Analysis of SLC7a11 mRNA expression in multiple cancer types from the TCGA data set repeatedly show 
overexpression of SLC7a11 as compared to normal control tissue. Abbreviations: BRCA, breast cancer; KIRC, 
kidney renal clear cell; LUAD, lung adenocarcinoma; LIHC, liver hepatocellular carcinoma; PRAD, prostate 
adenocarcinoma; LUSC, lung squamous cell carcinoma; KICH, kidney chromophobe; KIRP; kidney renal 
papillary cell carcinoma; HNSC, head and neck squamous cell; CHOL, cholangiocarcinoma; STAD, stomach 
adenocarcinoma; THCA, thyroid cancer; ESCA, esophageal carcinoma; USEC, uterine corpus endometrial 
carcinoma; BLCA, urothelial bladder carcinoma 
B. In TCGA tumors for which there is a difference in outcome between patients expressing varying levels of 




SLC7A11 expression correlates with KRAS mutation 
We previously stipulated that KRAS mutation may be a driving factor in the high 
production of ROS in cancer cells and their hypothesized sensitivity to alterations of redox 
homeostasis. Consistent with this model, we find that KRAS mutational status correlates 
positively with SLC7A11 expression (Figure 5-3). In summary, we find that SLC7A11 is 
overexpressed in malignant tissue, commonly elevated in many human tumors, is frequently 
associated with poor outcomes in multiple independent datasets, and particularly associated 
with activating KRAS mutations. 
 
Figure 5-3 SLC7A11 overexpression correlates with KRAS mutations 
KRAS mutant tumors in the TCGA (n = 424) data set show higher SLC7A11 expression levels than wildtype 




Deletion of Slc7a11 in established murine tumors slows growth and extends overall 
survival 
The following features make the system xc
- transporter an attractive drug target. First, 
genetic deletion or mutation of Slc7a11 in the mouse germline is well tolerated, resulting in 
generally healthy adult animals; however, when challenged with ROS stress, the animals are 
prone to ROS related pathologies such as kidney disease and neuronal toxicity at advanced 
ages137-141. Second, as a cell surface channel, the protein is easily accessible to therapeutic 
agents. Finally, a number of small molecules have been identified that inhibit system xc
- activity 
with varying potency90,99,142, illustrating that it is druggable. PE, IKE, and other erastin analogs 
potently inhibit SLC7A11 in vitro, but lack the appropriate pharmacological properties for 
effective systemic activity in mammals. Conversely, two FDA-approved drugs, sulfasalazine and 
sorafenib, exhibit off-target inhibition of system xc
-, but at substantially lower potencies 99,143.  
In the absence of a clinic-ready system xc
- inhibitor, we employed a dual recombinase 
genetic engineering strategy to evaluate the potential clinical utility of targeting system xc
- in 
established pancreatic tumors. Our strategy was guided by the successful “KPC” mouse model 
of PDA, which relies on conditional point-mutation of the endogenous KRAS and p53 genes with 
expression activated in pancreatic progenitors by Pdx1-Cre 64. In this strategy, we cross a novel 
Pdx-FlpO driver allele (Figure 5-4A) to mice bearing a homozygosed, floxed Slc7a11 allele in 
addition to a Rosa26CreERT2/CreERT2 allele, giving us tissue specific control over the recombination 
of FRT-based recombination and temporal control on CRE-based recombination. These mice 
are then crossed to KRASFSF-G12D/+; p53R172H/+; Slc7a11fl/fl mice, to produce our KRASFSF-G12D/+; 
p53R172H/+; PdxFlpOtg/+; Slc7a11fl/fl; Rosa26CreERT2/+ mice, hereafter referred to as KPFSR mice 
(Figure 5-4B). For a more thorough description of this breeding strategy, please refer to the 




Figure 5-4 PdxFlpO allele validation and KPSFR breeding scheme 
A. The PdxFlpo mouse was a gift of Scott Seeley. These mice were validated by crossing the strain 
with a FRT-STOP-FRT alkaline phosphatase reporter in which reporter expression was silenced until 
recombination via FRT would occur.  Images show founder lines exhibiting prominent alkaline 
phosphatase activity in the pancreas (frozen sections). 
B. Breeding strategy describing the production of KPFSR mice. 
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The resulting KPFSR mice were born at expected Mendelian ratios and appeared grossly 
healthy throughout development. To accelerate the development of PDA, KPFSR mice were 
injected with cerulean at ~8 weeks of age utilizing a dosing regimen known to cause chronic 
pancreatitis 144. These animals all developed PDA within several months, as detected by high 
resolution ultrasound and later confirmed by histopathology. Tumors from KPFSR mice 
appeared histopathologically identical to KPC mice, typically developing a single, focal tumor 
with moderate differentiation and evidence of a robust stromal desmoplasia (Figure 5-5A). The 
surrounding pancreatic tissues showed widespread evidence of pancreatitis, acinar-to-ductal 
metaplasia, and varying grades of PanINs (Figure 5-5B).  
 
Figure 5-5 Histological comparison of PDA and PDA development in KPC and KPFSR mice 
A. PDA in KPC and KPFSR mice bost present with a robust desmoplastic stroma and moderately 
differentiated, glandular structures. Two representative mice shown. 
B. Both KPC and KPFSR mice proceed to PDA formation through PanIN progression.  
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To directly assess the impact of blocking system xc
- function in pancreatic tumors, we 
intended to use tamoxifen to induce Cre-mediated deletion of Slc7a11 in mice with established 
tumors. To determine an optimal dose, first we carried out a pilot study to assess recombination 
efficiency in tumor tissues. After six days of daily tamoxifen administration at 200 mg/kg, near-
complete recombination was observed in the tumors assessed (Figure 5-6A), whereas there 
was incomplete recombination in neighboring tissues (Figure 5-6B).  
 
Using this dosing regimen, we then carried out an intervention survival study. Following 
cerulean induction, KPFSR mice were imaged periodically using high resolution 3D ultrasound 
Figure 5-6 Assessment of Slc7a11 recombination in tamoxifen treated mice  
A. Analysis of DNA recombination in tumors of mice treated with 200 mg/kg of tamoxifen for 6 
consecutive days. Samples were collected at 14 days post study initiation. Vehicle (corn oil) treated 
tumors exhibited essentially no recombination, producing one, clear amplicon at ~1300 base pairs 
(bp). Tumors treated with tamoxifen exhibited nearly complete recombination, producing one, clear 
~500 bp amplicon. 
B. Vehicle mice showed no off target recombination in neighboring tissues. Tamoxifen treated mice 
exhibited some degree of recombination in these tissues, producing two amplicons, one at ~1300 bp 
and another at ~500 bp. DNA from liver, spleen, and kidney was analyzed for this experiment. 
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to identify nascent tumors. Upon detection of a 4–7mm diameter tumor, mice were randomized 
to either tamoxifen or vehicle (corn oil) treatment arms, and then tumor growth was monitored 
twice weekly by 3D ultrasound. Post-hoc analysis shows that the distribution of tumor volume at 
enrollment was equivalent among treatment groups (Figure 5-7A). Following tamoxifen 
treatment, tumors typically grew more slowly or exhibited a period of stable disease; a subset 
showed transient regressions and one tumor completely regressed to the point of being 
undectable by ultrasound (Figure 5-7B, C). This mouse, however, eventually succumbed to a 
new, independent tumor. No comparable responses were observed in vehicle-treated animals. 
Tumor growth rates in mice treated with tamoxifen were significantly lower than those in the 
control arm (Figure 5-7D)145. Overall, tamoxifen-treated mice had a 2-fold increase in overall 
survival. Importantly, mice fed NAC in drinking water that had also been dosed with tamoxifen 
survived times comparable with our control arm, suggesting that oxidative damage is critical for 
mediating the benefits of system xc
- deletion, in vivo (Figure 5-7E).  We also examined the 
degree of recombination in tumors at endpoint after they had escaped the effects of Slc7a11 
deletion, using PCR. Notably, recombination was largely intact in the majority of tumors, 
highlighting the abilities to tumors to eventually overcome this genetic perturbation (Figure 5-8). 
To more fully assess the pathological effects of Slc7a11 deletion on tumors, we performed a 
standard histological examination of these samples.  Our results showed no clear differences in 
cleaved caspase-3 staining (a marker of apoptosis), Ki67 staining ( a cell proliferation marker), 
or PHH3 ( a marker of cells in mitosis) staining in endpoint samples (Figure 5-9A). However, 
histological analysis showed unique morphological features in tamoxifen-treated tumors when 
compared to controls (Figure 5-9B). These features were characterized by pockets of lipid 
inclusions surround intact nuclei, lending the region a “swiss cheese” appearance.  Lipid 
oxidation damage was sometimes associated with these features as evidenced by 




Figure 5-7 Slc7a11 deletion in established tumors slows growth and extends survival  
A. Analysis of tumor volumes at day of enrollment across groups of survival study. No significant 
changes were identified. Error = +/- SD. 
 
B. Tumor volumes are plotted as a function of days on study. N = 11, vehicle. N = 9, tamoxifen. N = 
4, tamoxifen/NAC. Error = +/- SD. * = p < .05 by unpaired t test. Vehicle is shown in gray, tamoxifen 
treated animals in red, and tamoxifen/NAC shown in blue. 
 
C. Tumor volumes for mouse in which Slc7a11 caused complete regression on initial tumor. A 
second tumor presented at day 18, however, and grew with normal kinetics. 
 
D. Tumor growth rates compared between treatment arms. Error = +/-SD. * = p<.05 
 
E. Kaplan-Meier survival curve showing significant extension of survival in tamoxifen-treated mice. * 





Figure 5-8 PCR analysis of recombination in endpoint tumors 
Agarose gel showing that in vehicle tumors, no recombination was readily apparent. Conversely, full 
recombination was observed in all endpoint tumors.  
Figure 5-9 Histological analysis of proliferation markers and morphological effects in 
tamoxifen-treated tumors 
A. Cleaved-caspase 3 (CC3), Ki67, and phosphohistone H3 (PHH3) staining qauntifiction. 
B. Histological comparison of endpoint tumors on survival study. Black arrows indicate areas of 
cellular damage. Red errors indicate areas of positive malondialdehyde staining. 
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together, these data suggest that therapeutic targeting of SLC7A11 may prove clinical beneficial 
in pancreatic cancer. 
Discussion 
      Multiple lines of research have begun to show the value of targeting unique metabolic 
shifts in cancer 146. In redox biology, cysteine has long been appreciated for its critical role in the 
production of GSH and in providing the basis for the disulfide chemistry that supports secondary 
and tertiary protein structure, but the precise relevance of these functions and the ability to 
target them for clinical benefit in cancer patients is still the subject of ongoing research. Here we 
show for the first time that the membrane amino acid transporter system xc
- can be specifically 
targeted to leverage a previously unidentified metabolic dependency in pancreatic cancer. 
Using human expression data we confirm that SLC7A11 is overexpressed in human 
pancreatic cancer when compared to normal pancreatic tissue. Interestingly, when comparing 
PanINs to PDA samples, we still see an upregulation of this gene, implying that SLC7A11 
overexpression may be a relatively late event in pancreatic cancer development. This is 
consistent with the current model of the relationship between oxidative stress and cancer onset: 
DNA damage caused by ROS is mutagenic and pro-oncogenic but cancer cells must eventually 
upregulate antioxidant function late in tumor development to promote survival in the face of 
mitochondrial oxidative stress56. Our results imply that SLC7A11 may play an important role in 
the progression of preneoplastic lesions to frank carcinoma in pancreatic cancer. As such, 
SLC7A11 activity may be an interesting biomarker for future study, a topic we will discuss in 
more detail in chapter 6.  
While the primary focus of this work has been on pancreatic cancer, we also use this 
chapter as an opportunity to explore the broad applicability of these results to other human 
cancers, using expression data as a surrogate for functional relevance in human cancer. We 
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show using a broad number of data sets that SLC7A11 is overexpressed in many human 
cancers, and as such may hold critical function in general cancer maintenance. We also 
highlight that in some cancers, SLC7A11 expression is correlated positively with poor prognosis. 
It may be possible that high expression of SLC7A11 can confer a survival advantage to tumor 
cells, especially those exposed to cytotoxic therapies. Another interpretation of these data is 
that SLC7A11 may promote the formation of more aggressive tumors in some cancer types, 
though it should be noted that these correlations do not apply to every tumor type. Finally, we 
show that KRAS mutational status positively correlates with SLC7A11 expression. This is 
consistent with previous reports that KRAS mutation can activate a cellular antioxidant program 
mediated by Nrf2 transcription of antioxidant genes59. 
While there is some work to suggest that targeting redox dependencies in pancreatic 
cancer can retard tumor growth54,93, we provide the first evidence that targeting cystine transport 
directly in a GEMM can cause slowdown or even regression in the growth of established 
pancreatic tumors and extend overall survival in mice. In fact, we report the first complete 
regression of a pancreatic tumor in a model of this type. It is important to note that in our model, 
we cause global deletion of Slc7a11, making it impossible to known if these effects cell 
autonomous or non-autonomous. However, we confirm that treatment of mice with an 
antioxidant (NAC) can “rescue” the phenotype in these tumors, restoring their initial growth 
rates, suggesting that these effects are primarily oxidative in nature. While the survival benefit 
conferred by this genetic therapy is statistically significant, it is interesting to note that the 
survival rates in all mice that die before 8 days on study are essentially equivalent. This may 
highlight one of two points: first, that Slc7a11 gene function is not rendered completely 
ineffective until up to 8 days following enrolment on study; or second, that only a subset of mice 
responds to this gene therapy. It is also critical not to lose sight of the fact that eventually all 
mice do succumb to their tumors, despite the loss of Slc7a11 function. This underscores the 
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stubborn ability of pancreatic tumors to overcome stress, but may also offer an opportunity to 
study modes of resistance to cystine import blockade in efforts to make this treatment approach 
more efficacious. In closing, we offer the first report of SLC7A11 expression in a variety of 
human cancers and the creation of a novel mouse model of pancreatic cancer in which we 
delete Slc7a11 to assess its functional relevance in PDA. We show that SLC7A11 is 
overexpressed in multiple cancer data sets when compared to normal tissue and that deletion of 





































Cysteine import as a unique metabolic dependency in pancreatic cancer 
 Many lines of current inquiry in pancreatic cancer have focused on illuminating the 
effects of KRAS mutation on vital metabolic systems in the cancer cell. While many 
breakthroughs have been made with regards to glucose metabolism, amino acid metabolism, 
and nutrient import and scavenging40,46,48,49,54; redox biology has recently become an emerging 
theme in this field59,93. Cysteine, given its critical antioxidant functions, presented an intriguing 
metabolite to explore in the context of pancreatic cancer, a prototypical RAS-driven malignancy. 
As such, we endeavored to elucidate what role this amino acid may play in maintaining the 
redox state of pancreatic cancers and if targeting its import would yield any potentially useful 
therapeutic effects.  
A primary concern when testing new therapeutic approaches is that targeting vital 
cellular systems will limit their clinical utility given the chances that it may cause undue toxicity in 
normal tissues. Such is the classical problem associated with chemotherapeutic cancer 
interventions, which are associated with myriad side effects and whose administration must 
often be de-escalated or even halted in light of declining patient health. Like pancreatic cancer 
cells, it is possible that normal cells also require cysteine for survival. However, perhaps 
somewhat surprisingly, germline knockout of Slc7a11 produces viable litters with no obvious 
phenotypes147. This finding is actually consistent with the expression pattern of system xc
-, 
which has limited expression in human tissues. SLC7A11 mRNA is most prominently expressed 
in the central nervous system, spinal cord, and immune organs (thymus, spleen, lymphatic 
tissue), with some expression in the pancreas148, suggesting it may play a rather limited role in 
normal tissue function. In keeping with these phenotypic motifs, the sut mouse, which bears a 
large deletion on chromosome 3 that compromises system xc
- function, exhibits only two 
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reported phenotypes: a deficiency in pigment formation yielding its characteristic gray fur, and 
some brain atrophy140, neither of which appear to affect overall lifespan or neurological function. 
As such, we suggest that cysteine may represent a selective and potent dependency in 
pancreatic cancer. Most importantly, this dependency can be targeted pharmacologically by way 
of its primary transporter, setting the stage for translational work to confirm the validity of these 
results in human patients. 
To formally test differences in sensitivity between normal and malignant tissue, we 
propose using a recently pioneered organoid model which allows for the facile three-
dimensional culture of normal pancreas, early pancreatic cancer lesions, and frank 
carcinoma149. In these experiments, organoids derived from both normal and neoplastic human 
tissue would be cultured and could be tested in manners analogous to methods laid out herein. 
As an example, early experiments would involve culturing these cells in media containing 
diminishing concentrations of cysteine and then subjected to standard viability assays. A similar 
series of dose escalation experiments testing the efficacy of a system xc
- inhibitor in these 
systems would follow. Treating these cells concomitantly with various rescue agents could help 
interrogate what sorts of cell death effects, in any, were occurring in these various organoids. 
Furthermore, it is possible to use KPFSR mice to derive novel organoids over which genetic 
control of Slc7a11 could be exerted. In this system, a viral Cre could be utilized to cause 
deletion of Slc7a11 with temporal control and could help us untangle if the effects of Slc7a11 
deletion that we have discussed in our model are in fact cell autonomous or non-autonomous. 
Furthermore, this system could be refined to allow us to control KRAS mutational activation to 
test if RAS mutations themselves bear any importance on conferring sensitivity to cysteine 
deprivation, as is implied by some our work.  
Determining the role in cysteine import in pancreatic cancer development 
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 In this study, we chose to focus on the role that system xc
- plays in tumor maintenance, 
since patients present clinically with late-stage cancer and that approach is the most stringent 
for probing for translatable results. However, we left unexplored what role, if any, that this 
system plays in the early evolution of PDA. ROS and the role they play as signaling molecules 
is not to be understated: certainly their toxicity makes them a palatable bogeymen for many 
cancer researchers and, indeed, in the popular scientific consciousness, but a large body of 
record confirms that they are important signaling molecules with complicated regulatory 
functions150.  
It may be possible that SLC7A11 plays an important role in limiting ROS accumulation in 
developing preneoplastic lesions and that in the absence of this control, initiating lesions fail to 
progress. Preliminary results from our study in mice that were euthanized at earlier time points 
during our survival study show evidence of a very pronounced cell death effect in nests of 
acinar-ductal metaplasia (ADM) in diseased pancreata (Figure 6-1). Here, we see the tissue is 
lent the same “swiss cheese” appearance seen in tamoxifen treated tumors. Interestingly, 
whereas ADM in KPC often show evidence of apoptosis as measured by cleaved-caspase 3 
staining, the ADM we observe in KPFSR mice do not. These early results suggest that 
SLC7A11 function may be critical for PanIN progression, but further work would be required to 
validate this claim. We would propose an early intervention study, in which mice that do not 
have signs of overt disease are treated with tamoxifen using the dosing regimen we have 
already established in this work. These mice could then be monitored for tumor formation as 
compared to control animals, and the time to tumor onset could be recorded. Mice would be 
sacrificed at established time points following study initiation, in efforts to capture effects of 
Slc7a11 deletion on PanIN formation and tumor initiation. Once again, our model also allows us 
to also test the genetic contribution of KRAS or p53 mutations to this process. Using caerulein 
to induce ADM in the normal pancreas of mice with difference genetic background (KRAS 
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mutant, p53 mutant, or double mutant) and then deleting Slc7a11 in these mice using tamoxifen  
 
could help us determine if these effects are merely associated with any pro-inflammatory event 
or if they require a specific mutational burden. Using these approaches, we could determine if 
cystine import may play a critical role in tumor development and if it may be leveraged in the 
context of a preventative therapy. 
Overcoming resistance to system xc
- deletion 
Normal KPC-ADM KPFSR-ADM  
HE HE 
CC3 CC3 
Figure 6-1 Effects of Slc7a11 deletion on acinar-ductal metaplasia (ADM) in KPC and KPFSR 
mice 
Histological examination of ADM lesions in KPC and KPFSR mice. Here, KPFSR mice have been 
treated with tamoxifen to induced recombination of Slc7a11. Arrows indicate CC3 positive cells. 
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 Our work highlights the first reported case of targeting system xc
- to yield appreciable 
survival benefit in a GEMM, but we are forced to reckon with the fact that, in spite of these 
efforts, all of these experimental mice eventually succumb to their disease. Certainly, this is the 
not the first case of a highly intractable cancer overcoming therapeutic intervention. Indeed, 
there is a large body of scientific literature attempting to solve the problem of overcoming drug 
resistance, both acquired and intrinsic, in many cancers151-156. Our results do raise a pertinent 
question in this regard: how exactly do pancreatic tumors in mice overcome the deletion of 
Slc7a11?  
We provide evidence that these tumors in most cases either fail to grow or even 
decrease in size when faced with this obstacle, but still they manage to surmount this difficulty 
and eventually grow to appreciable sizes. We have a hint as to how this may be happening from 
some of our in vitro work: in cell culture conditions, we show one method that pancreatic cancer 
cells use to overcome the effects of system xc
- blockade is by upregulating macropinocytosis. 
To test if this is true, the tumors of KPSFR mice treated with tamoxifen or vehicle would be 
directly injected with a high molecular weight fluorescent dextran (analgous to our in vitro 
experiment) to help us quantify macropinosome formation. Should these results confirm that 
macropinocytotic activity was increased in tamoxifen treated tumors, we would undertake an 
intervention study featuring co-treatment of tamoxifen and the macropinocytosis inhibitor, EIPA, 
utilizing an administration protocol as previously describe48. Monitoring tumor growth by 
ultrasound, we would be able to determine response rates and discern the effect of EIPA co-
treatment on the health of these tumors. 
While macropinocytosis would provide one possible answer to the question of how 
tumors overcome system xc
- dysfunction, other possibilities cannot be ruled out. While we did 
not find that transsulfuration mediated sensitivity to system xc
- inhibition, it still offers a 
compelling explanation for how cells can overcome cysteine deprivation. A more exploratory 
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approach in the context of our GEMM may yield more inclusive answer regarding how tumors 
overcome this metabolic stress. We propose using an RNA-seq analysis to unveil potential 
transcriptional changes that cooperate to promote tumor survival in the absence of cystine 
import. 
Many current treatment modalities in pancreatic cancer focus on using 
chemotherapeutic combinations to generate the keenest cytotoxic effects in tumors. In our 
study, we limit our research to exploring one therapeutic intervention, but would suggest that 
combination of this genetic therapy with other agents may prove even more efficacious. FDA-
approved drugs which are known to cause oxidative stress would be an attractive class of 
agents to test in this model, but certainly other standard-of-care chemotherapeutics would also 
be appropriate for testing. As an example, we propose testing cisplatin, a platinum-based 
chemotherapy that has recently been reported to cause ROS accumulation in normal tissues157-
159, in combination with Slc7a11 deletion to determine efficacy. Furthermore, focused radiation 
treatment can also cause ROS accumulation and may synergize impressively with Slc7a11 
deletion160. It may even be compelling to turn to a long debated anti-cancer therapy, vitamin C, 
in this context to exacerbate these phenotypes, since work from the Cantley laboratory has 
shown that vitamin C is effective in KRAS and BRAF mutant colorectal cancer by exacerbating 
oxidative stress161. 
Targeting GSH synthesis and CoA function to cause ferroptosis 
 Our work refines the current model of the mechanism of ferroptosis by suggesting that, 
while GSH depletion is critical for mediating these effects, it alone is not sufficient to cause them 
in this context. These results are consistent with early phase I trials of BSO in combination with 
melphalan, which demonstrated excellent pharmacodynamic effects and little associated 
toxicity, but only produced measurable responses of 2 of 28 patients162. The combination has 
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moved into a phase II trial that was completed in 2016, but not results have yet been reported 
for this study. We contend that BSO alone is unlikely to cause responses as a monotherapy, but 
are encouraged by the possibility that, given its favorable toxicity profile, it can be paired with 
other agents to create robust effects. Our work suggests that targeting other cysteine-regulated 
pathways may enhance this effect, but this remains to be borne out experimentally. We 
hypothesize that CoA synthesis and its numerable functions are the secondary mediator of the 
effects of cysteine deprivation. As such, targeting CoA synthesis in combination with BSO 
treatment may prove beneficial in pancreatic cancer. One function of CoA is to serve as a 
precursor for the production of mevalonate, a key molecule required for the synthesis of 
cholesterols and other isoprenoids (e.g, coenzymeQ10). In this work, we show that the effects 
of system xc
- inhibition can be fully rescued treatment with idebanone, a cell-permeable form of 
coenzyme Q10. With these data in mind, we propose dosing tumor bearing mice with BSO in 
combination with statin class drugs to inhibit the mevalonate pathway. This is a particularly 
appealing combination because both compounds are FDA approved and have limited side 
effects. Interestingly, statin use has now been correlated with a 34% decrease in pancreatic 
cancer risk in males, suggesting that this approach may even have a preventative benefit163. 
In vivo mechanisms of ferroptosis and its relevance in cancer 
 The primary goals of breeding the KPFSR mouse were two-fold: first, to test the effect of 
Slc7a11 deficiency in intact tumors; second, to create a conditional model system in which we 
can determine if system xc
- inhibition in vivo can cause ferroptosis. To date, precious little work 
has been done to show if ferroptosis occurs in living tissues. One recent publication highlights 
that GPX4 knockout induced by tamoxifen treatment causes acute renal failure and kills mice164. 
This work shows profound images of the damage incurred in renal tubules and the liver after 
deletion of GPX4, which the authors claim is in vivo ferroptosis. Here, the authors perform 
elegant work showing that these effects can be ameliorated by liproxstatin-1, which they identify 
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as an inhibitor of ferroptosis by way of large-library compound screen to identify chemicals that 
rescue Gpx4 knockout MEFs from ill effects. Using this compound, they rescue the effects of 
GPX4 deletion on livers subjected to transient ischaemia/reperfusion. These may be some of 
the first reports of in vivo ferroptosis in native animal tissues, albeit not in a therapeutic setting. 
Building on this type of research, our in vivo work shows that the survival benefit 
conferred by Slc7a11 deletion cancer be abrogated by co-treatment with NAC, a known rescuer 
of ferroptotic cell death in the context of system xc
- malfunction. These findings are also 
consistent with data presented in our in vitro work. However, it may still be too early to claim that 
we are seeing ferroptosis in tumors. Certainly, the lesions we see in endpoint tumors are unlike 
those seen in apoptosis and seem analogous to the morphological effects of ferroptosis on cells 
in culture (Figure 6-2). To date, characterizing ferroptosis has been accomplished by rescuing 
its effects using both a lipophilic antioxidant (e.g. Fer-1) and by iron chelation (e.g. DFO). To 
explore this question, we propose attempting to “rescue” to survival benefit in our model with 
liproxstatin-1, ferostatin-1, and DFO. Adding these arms to the study will help elucidate the 
precise mechanism by which Slc7a11 deletion exerts its effects. It will also be possible to plan 
to short-term study in which animals are sacrificed at early signs of tumor response to generate 
samples critical for determining the molecular mediators of the effects we see herein. In vivo 
metabolomics using a mass spectrometric readout can be used to determine metabolite levels 
in tumor samples, comparing responding tumors and vehicle tumors to generate data 
implicating particular molecules in the tumor growth inhibition we see in our experiments. It 
would also be fruitful to perform a full lipidomics screen on these same samples to determine 
what role, if any, changes in lipid biosynthesis or fatty acid oxidation state play in executing the 
effects in these tumors. In conclusion, we believe that the KPSFR model can play a vital role in 
untangling the precise mechanisms of ferroptosis in living tissues and can be easily modified to 
test other hypothesis regarding cystine import and other vital metabolic functions. The mice 
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generated in this study will hopefully go on to serve as an invaluable resource, not only in our 
laboratory, but also in the greater cancer biological field, to help test new therapeutic regimens 









Figure 6-2 High magnification images of the effects of Slc7a11 deletion on pancreatic tumors 
100x images of normal pancreatic tumor (left panel) and a characteristic lesion in tumors in mice that 
were treated with tamoxifen to delete Slc7a11 (right panel). We note the presence of cells with intact 
nuclei, ballooned membranes, and lipid inclusions (marked with black arrows). Scale bars are 20μm. 
87 
 
MATERIALS AND METHODS 
Chapter 2 
Cell lines, cell culture, and viability assays 
All cell lines were obtained from ATCC and tested negatively for mycoplasma infection. Cells 
were maintained under standard conditions at 37ºC and 5% CO2. Cells were grown in DMEM 
(Life Technologies, 12430-054) supplemented with penicillin and streptomycin (Corning, 30-
003-CI), 10% FBS (Life Technologies, 10438-034), and MEM NEAA (Life Technologies, 11140-
050), unless otherwise indicated. For cysteine depletion experiments, cells were cultured in 
DMEM lacking met/cys (Life Technologies, 21013-024), supplemented with 200 mM methionine 
(Sigma, M9625), 4mM glutamine (Life Technologies, 25030-081), 10% FBS, penicillin and 
streptomycin and varying concentrations of cystine (Sigma, C8755), depending on the given 
experiment. For cell viability experiments cells were plated in a 96-well plate format. PANC-1 
cells were plated at 4000 cells per well; MIA PaCA-2, BxPC3, and AsPC1 cells were plated at 
8000 cells per well. Cells were allowed to seed overnight, and subsequently treated with 
compounds at indicated concentrations and for indicated lengths of time. The following is a list 
of all chemical compounds used in cell culture experiments: ZVAD-FMK (SelleckChem, S7023), 
Bafilomycin A1 (Sigma, B1793), Necrostatin-1s (BioVision, 2263-1), Ferrostatin-1 (Sigma, 
SML0583), N-acetyl-L-cysteine (Sigma, A9615), buthionine sulfoxamine (Sigma, B2515), 
deferoxamine (Sigma, D9533), EIPA (Sigma, A3085), PE and IKE (provided by the Stockwell 
laboratory), staurosporine (Sigma, S4400), N-acetyl-cysteine (Sigma, A9165), beta-
mercaptoethanol (Sigma, M6250). Compounds were formulated according to the manufacturer’s 
instructions. All viability assays were carried out using the AlamarBlue reagent (Thermofisher, 
88952) according to the manufacturer’s instructions. In brief, 10 μL of AlamarBlue reagent was 
added each well containing 100 μL of experimental media. Plates were gently agitated for 1 
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minute to promote adequate mixing. Once wells had reached uniform color, plates were 
incubated at standard culture conditions indicated above for 1-4 hours. Plates were 
subsequently assessed for fluorescent readout on a Promega plate reader using the appropriate 
filter.  
Light and fluorescent microscopy 
Still transmitted light images were captured on an Olympus CKX41. Time lapse images and 
fluorescent microscopy images were captured on a Nikon A1RMP. One image was captured 
every two minutes for up to 24 hours post treatment initiation. Fluorescent time lapse 
microscopic images were captured on an IncuCyte ZOOM system. One image was captured in 
every channel (transmitted light, red, and green) once every 15 minutes between 2 and 12 
hours post treatment initiation. Cells were plated in a 6-well plate format, (PANC-1: 250,000 
cells per well, MIA PaCa2: 400,000 cells per well) 16 hours prior to drug treatment and 
subsequent staining. Cells were stained with C-11 Bodipy (Invitrogen, C10445) at a 
concentration of 2uM for 30 minutes prior to time lapse imaging. Cells were washed with PBS 
three times and incubated in Live-Cell Imaging Solution (Life Technologies, A14291DJ) during 
the duration of live-cell imaging. To detect lipid ROS at static time points by fluorescence 
microscopy, cells were plated in 1u-Slide 8 well ibiTreat dishes (ibidi, 80827). PANC-1 cells 
were plated at 30,000 cells per chamber, MIA PaCa2 cells were plated at 60,000 cells per 
chamber. Cells were seeded overnight and subsequently subjected to indicated treatments for 
indicated times. Upon experiment completion, cells were visualized on a Nikon A1RMP using a 
FITC filter. 
Flow cytometric detection of ROS 
PANC-1 and MIA PaCa-2 cells were plated in a 12 well format at 100,000 cells and 200,000 
cells per well, respectively. Cells were allowed to seed overnight and were subjected to drug 
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treatments for indicated times. Cells were then incubated for 30 minutes in live-cell imaging 
solution containing the pertinent ROS dyes at the following concentrations: C-11 Bodipy, 2 µM;  
H2DCFDA, 10 µM (Invitrogen, C6827). Cells were then washed with PBS, trypsinized with .25% 
trypsin (Life Technologies, 25200-056), and neutralized with FBS. Cells were strained through a 
40uM strainer (BD Falcon), and analyzed on a MACSQuant Analyzer 10. A minimum of 8000 
cells were analyzed per condition. Software analysis was carried out using FlowJo V10. 
 
Chapter 3 
13C labeling and metabolomics analysis (NOTE: all metabolomics materials and methods 
are detailed here and will be referred to in future chapters as necessary) 
PANC-1 and MIA PaCa-2 cells were plated 16 hours prior to drug treatment at 1.5 million 
millions cells and 3 million cells per 10 cm dish, respectively. Cells were cultured in DMEM 
containing 10% dialyzed FBS (ThermoScientific, 26400036), but lacking either cysteine or 
methionine (see Chapter 2). All experiments were set up in biological triplicate. 13C carbon in 
metabolites was assessed by growing PANC-1 and MIA PaCa-2 in the media described above, 
which was then supplemented with 13C methionine or 12C cystine, in presence or absence of 
inhibitors.  
At the end of indicated time points, the medium was aspirated saving 1 ml for polar metabolite 
extraction. Cells were lysed with dry-ice cold 80% methanol and extracts were incubated in -
80ºC for 10 min. Samples were then centrifuged at 4000 rpm for 10 min at 4 °C and the 
supernatant was stored at -80 °C till further analyses. Metabolite extraction utilizing medium 
samples was done by adding 1 ml of medium to 4 ml 100% methanol, followed by incubation at 
-80 °C for 30 minutes and centrifugation at 14,000 rpm for 10 min at 4 °C. Protein 
concentrations were determined by processing a parallel 10 cm dish and used to normalize 
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metabolite fractions. Based on protein concentrations, aliquots of the supernatants were 
transferred to a fresh micro centrifuge tube and lyophilized using a speed vac. Dried metabolite 
pellets from cells or media were re-suspended in 35 μl 50:50 MeOH: H2O mixture for LC–MS 
analysis.  
For steady state, 5 μl of samples was injected onto a Agilent 1290 UHPLC as above and 
separated using a Waters Acquity UPLC BEH amide column (2.1 x 100mm, 1.7µm) column. For 
negative ion acquisition, the mobile phase (A) consisted of 20mM ammonium acetate, pH 9.6 in 
water, and mobile phase (B) was ACN.  Gradient program: mobile phase (B) was held at 85% 
for 1 min, increased to 65% in 12 min, then to 40% in 15 min and held for 5 min before going to 
initial condition and held for 10 min.  The column was kept at 40 ̊C and 3 µl of sample was 
injected into the LC-MS with a flow rate of 0.2 ml/min.  Calibration of TOF MS was achieved 
through Agilent ESI- Low Concentration Tuning Mix. 
Optimization was performed on the 6490 QqQ in negative or positive mode individually for each 
of 220 standard compounds to get the best fragment ion and other MS parameters for each 
standard.  Retention time for each standard of the 220 standards was measured from pure 
standard solution or a mix standard solution.  The LC-MS/MS method was created with dynamic 
dMRMs with RTs, RT windows and MRMs of all the 220 standard compounds.  
In both acquisition modes, key parameters of AJS ESI were: Gas temp 275 ̊C, Gas Flow 14 
l/min, Nebulizer at 20 psi, Sheath Gas Heater 250 ̊C, Sheath Gas Flow 11 L/min, Capillary 3000 
V.  For negative mode MS: Delta EMV was 350 V, Cycle Time 500 ms and Cell accelerator 
voltage was 4 V, whereas for positive acquisition mode MS: Delta EMV was set at 200 V with no 
change in cycle time and cell accelerator voltage.    
The QqQ data pre-processed with Agilent MassHunter Workstation Software Quantitative 
Analysis were post-processed for further quality control in the programming language R. We 
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calculated coefficient of variation (CV) across replicate samples for each metabolite given a cut-
off value of peak areas in both the positive and the negative modes. We then compared 
distributions of CVs for the whole dataset for a set of peak area cut-off values of 0, 1000, 5000, 
10000, 15000, 20000, 25000 and 30000 in each mode. A noise cut-off value of peak areas in 
each mode was chosen by manual inspection of the CV distributions. Each sample is then 
normalized by the total intensity of all metabolites to reflect the same protein content as a 
normalization factor. We then retained only those metabolites with at least 2 replicate 
measurements. The remaining missing value in each condition for each metabolite was filled 
with the mean value of the other replicate measurements. Finally, each metabolite abundance 
level in each sample was divided by the median of all abundance levels across all samples for 
proper comparisons, statistical analyses, and visualizations among metabolites. The statistical 
significance test was done by a two-tailed t-test with a significance threshold level of 0.05. The 
p-values were not adjusted in favor of more flexible biological interpretation.  
For the 13C cystine/methionine label incorporation studies, a Agilent 1260 UHPLC combined 
with a 6520 Accurate-Mass Q-TOF LC/MS was utilized. Agilent MassHunter Workstation 
Software LC/MS Data Acquisition for 6200 series TOF/6500 series Q-QTOF (B.06.01) was used 
for calibration and data acquisition. A Waters Acquity UPLC BEH amide column (2.1 x 100mm, 
1.7µm) column was used with mobile phase (A) consisting of 20 mM NH4OAc in water pH 9.6, 
and mobile phase (B) consisting of ACN. Gradient program: mobile phase (B) was held at 85% 
for 1 min, increased to 65% in 12 min, then to 40% in 15 min and held for 5 min before going to 
initial condition and held for 10 min.  The column was at 40 ̊C and 3 µl of sample was injected 
into the LC-MS with a flow rate of 0.2 ml/min.  Calibration of TOF MS was achieved through 
Agilent ESI-Low Concentration Tuning Mix. 
Key parameters for both acquisition modes were: mass range 100-1200 da, Gas temp 350 C ,̊ 
Fragmentor 150 V, Skimmer 65 v, Drying Gas 10  l/min, Nebulizer at 20 psi and Vcap 3500 V, 
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Ref Nebulizer at 20 psi. For negative mode the reference ions were at 119.0363 and 980.01637 
m/z whereas for positive acquisition mode, reference ions at 121.050873 and 959.9657 m/z 
For 13C-labeling data analysis, we used Agilent MassHunter Workstation Software Profinder 
B.08.00 with Batch Targeted Feature Extraction and Batch Isotopologue Extraction and 
Qualitative Analysis B.07.00. Various parameter combinations, e.g. mass and RT tolerance, 
were used to find best peaks and signals by manual inspection. Key parameters were: mass 
tolerance = 20 or 10 ppm and RT tolerance = 1 or 0.5 min. Isotopologue ion thresholds, the 
anchor ion height threshold was set to 250 counts and the threshold of the sum of ion heights to 
500 counts. Coelution correlation threshold was set to 0.3. 
All other bioinformatics analyses including graphs and plots were done using R/Bioconductor. 
Macropinosome Visualization and Quantification 
Glass coverslips were treated with poly-L-lysine (PLL) (Sigma, P5899), according to 
manufacturer’s instructions. Cells were seeded onto glass coverslips. 24 hours after seeding, 
cells were treated with PE, EIPA (Sigma, A3085), vehicle, or PE+EIPA co-treatment at the 
indicated doses.After preliminary experiments, 50 μM was determined to be the effective dose 
for EIPA that both inhibits macropinosome formation and limits off-target cytotoxic effects. This 
dose was used for all experiments thereafter. Macropinosomes were visualized by the uptake of 
high molecular weight (70kDa) TMR-dextran (ThermoFisher, D1818), which was added to the 
medium prior to the conclusion of the drug treatment time-point, at a final concentration of 500 
μg/mL for 30 minutes at 37℃. After the 30-minute incubation the cells were gently rinsed three 
times with cold PBS then immediately fixed in formalin (4% formaldehyde in PBS for 30 minutes 
at room temperature. Cells were DAPI-treated to stain the nuclei, and the coverslips were 
mounted onto slides using Vectashield Mounting Medium (Vector Laboratories, H-1000). Slides 
were left to dry overnight in dark room at 4℃. Images were captured using an Axiovert 200 
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inverted fluorescent microscope (Zeiss, 100x oil immersion lens, 10 randomly selected fields per 
sample) and analyzed as previously described 48,165. Macropinosomes were defined as those 
particles with a circularity index between 0.5 and 1.0, and with an area of 0.20-20.0 microns2, in 
keeping with literature classification of macropinosomes. The number of macropinosomes per 
cell was divided by the number of intact cells present, as visualized via DAPI and brightfield 
staining. We termed this the “macropinocytotic index” (average number of macropinosomes per 
cell). All 10 fields were analyzed for each sample. 
Cell Culture Viability Assays 
Cell culture assays were carried out as described in the Chapter 2 section. New compounds 
used in this section: propargyglycine (Sigma, 81838), EIPA (Sigma, A3085), buthionine 
sulfoxamine (Sigma, B2515). 
 
Chapter 4 
13C labeling and metabolomics analysis 
See Chapter 3 
Cell Culture Viability Assays 
Cell culture assays were carried out as described in Chapter 2. New compounds used in this 






Microarray data. Gene expression data from studies comparing pancreatic ductal 
adenocarcinoma specimen with normal pancreas parenchyma were downloaded from the Gene 
Expression Omnibus (GEO) using the GEOquery R166 package 167 and the following accession 
numbers: GSE32676 168, GSE19650 169, GSE16515 170, GSE62452 171 and GSE71729 172. 
U133A-CEL files from 173,174 were obtained from ArrayExpress under accession number E-
MEXP-950 and normalized using GCRMA 175. The following samples were excluded because of 
outlier behavior during exploratory data analysis: NPD15, T55, TPK9, NPK13. For all studies, 
probes were collapsed at the gene level using their mean normalized expression. 
TCGA data. RNA-Seq V2 expression, clinical and mutation data were downloaded for all 
available TCGA tumor types using the RTCGAToolbox R package 176.  The run date was set to 
“2016-01-28”. A detailed script on further pre-processing steps is provided separately. 
Differential Gene Expression analysis 
Genome-wide differential gene expression analysis normal tissue of origin and tumor tissue 
were calculated using the limma 177 R package using (gc)rma-normalized expression data for 
microarray studies and log2-transformed normalized count data for the TCGA cohorts. If normal 
and tumor samples were matched, i.e. from the same patient, a paired design was specified in 
the design formula.  
Effect size meta-analysis.  
In order to evaluate evidence on the differential expression of SLC7A11 from 6 studies where 
global expression in normal pancreatic tissue was compared to PDA, the effect size (i.e. log2 
fold change) and its standard error were extracted from the respective genome-wide differential 
expression analysis, which was carried out using the limma R package. Meta-analysis was 
carried out using the metafor 178 R package. Both random and fixed effect models were fit using 




The association of SLC7A11 expression status with disease outcome was evaluated using a 
log-rank test as implemented in the survdiff function from the survival 179 R package. Patients 
were grouped into tertiles according to normalized SLC7A11 expression and differences in 
outcome were assessed between the upper and lower tertile. 
 
Animal Breeding and genotyping 
All studies were carried out in accordance with the relevant institutional guidelines of Columbia 
University. 
Generation of Pdx1-FlpO mice 
The proximal 6kb promoter of the Pdx1-Cre transgene (Gu et al., 2002; Hingorani et al., 2003) 
was fused to the start codon of mammalian codon-optimized, thermostabile Flp recombinase 
(FlpO)(Raymond and Soriano, 2007), with subsequent fusion of the 5’ end of the FlpO open 
reading frame to the hGH polyadenylation signal sequence using the In-Fusion cloning system 
(Clontech) according to the manufacturer’s instructions. The Pdx1-FlpO cassette was excised 
from a large-scale plasmid preparation, gel-purified, and microinjected into the pronuclei of 
fertilized FVB oocytes at the Gladstone Transgenic Mouse Core. Following implantation, birth, 
and weaning, transgene-bearing founder mice were identified via PCR and maintained on an 
FVB background. 
Pdx1-FlpO founders were crossed to homozygous FVB alkaline phosphatase Flp reporter mice 
(gift, Dr. Susan Dymecki, Harvard University), Pdx1-FlpO-harboring progeny sacrificed at 2 
months of age, and skin, brain, liver, pancreas, kidney, lung, stomach, duodenum, small 
intestine, colon collected and flash frozen in liquid nitrogen. Frozen sections of each were cut, 
alkaline phosphatase histochemistry performed (Vector Laboratories), and sections examined 
microscopically. Founder lines exhibiting prominent alkaline phosphatase activity in the 
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pancreas were backcrossed an additional five generations and this process was repeated to 
identify founder lines exhibiting stable transgene expression. 
Pdx1-FlpO mice were crossed with Kras+/LSL-G12D;p53FRT/FRT, Pdx1-FplO; Kras+/LSL-G12D;p53FRT/+ 
progeny aged for 3 months or until they had reached humane endopoint, and pancreas, 
stomach, duodenum, small intestine, colon, skin, lung, and brain examined grossly and 
microscopically for the presence of neoplasia. 
Generation of SLC7A11 conditional knockout mice 
Initially, Slc7a11 conditional potential mice were imported from the IMPC repository (EMMA ID: 
10001, strain designation Slc7a11tm1a(EUCOMM)Wtsi). These mice were crossed to homozygous 
ACTB: FLPe mice (Jackson Laboratory, Stock no. 003800) to create SLC7A11 conditional mice 
in which loxP sites surround exon three of the gene. Using a combination of the Pdx1-Flpo, 
KRASFSFG12D (Jackson Laboratory, Stock no. 008653), p53R172H (Jackson Laboratory, Stock no. 
008652), Rosa26CreERT2 (Jackson Laboratory, Stock no. 008463), and our newly made 
Slc7a11fl/fl mice, we were able to generate a new strain of genetically engineered mouse model 
akin to the KrasLSL-G12D/+;p53LSL-R172H;Pdx1-Cre (KPC) mouse 64, but in which we have 
temporal control of the deletion of Slc7a11 using tamoxifen. We term these mice KRASFSF-G12D/+; 
p53R172H; Pdx1-Flpotg/+; Slc7a11fl/fl; Rosa26CreERT2/+, KPFSR mice. 
Genotyping 
Genotyping was carried out using protocols provided by Jackson Laboratory for all strains 
obtained from this vendor. 
Slc7a11fl/fl genotyping was carried out as follows: 
Forward primer: 5’-tgggttggtctctggtgatc-3’ 





1. 94ºC 3 minutes  
2. 94ºC 1 minute 
3. 60ºC 2 minutes 
4. 72ºC 1 minute 
Cycle to step 2, 29 times. 
5. 72ºC 5 minutes 
6. 4ºC forever 
Expected amplicons: 
Slc7a11 mice: 386 bp 
WT mice: no amplicon 
  
 
Slc7a11 recombinatorial genotyping was custom designed as follows: 
Forward primer: 5’-tgg gtt ggt ctc tgg tga tc-3’ 
Reverse primer:5’-ctt aac ccc agc acc att cg-3’ 
Cycling conditions: 
1. 95ºC 2 min 
2. 95ºC 1 min 
3. 56ºC 30 seconds 
4. 72ºC 1 min 
Cycle to step 2, 34 times 
5. 72ºC 5 min 
6. 4ºC forever 
Expected amplicons:  
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Slc mouse unrecombined  approx. 1300 bp 
Slc mouse recombined approx. 500 bp 
WT mouse approx  1240. 
 
Survival study 
 KPSFR mice were treated at approximately 42 days of age with caerulein (Sigma, C9026) at 
250 ug/kg by intraperitoneal injection for 5 consecutive days to induce chronic pancreatitis and 
accelerate tumor formation, as per previous reports 180-182. Tumor formation was monitored 
initially by once weekly palpation and upon positive palpation, but twice-weekly ultrasound. 
Once the average diameter of tumors of the pancreas was 4-7 mm in size, mice were randomly 
enrolled into the survival study. Mice were treated with either corn oil (Sigma, C8267) or 
tamoxifen (Sigma, T5648) at 200 mg/kg by oral gavage for 6 days. Mice were euthanized once 
they reached endpoint criteria in concordance with IACUC regulations. Samples were either 
fixed in formalin overnight at 4ºC, fixed in PFA at 4ºC overnight followed by sucrose-mediated 
water displacement for 24 hours at 4ºC, frozen in OCT, or flash frozen in liquid nitrogen. 
Pathology and immunohistochemistry 
Samples that had been fixed in formalin were washed in 70% ethanol and subjected to standard 
dehydration processing to prepare them for mounting in paraffin wax blocks. Paraffin blocks 
were sectioned on a Leica RM 2235 at 5 μM thickness. The sections were mounted on charged 
slides and heated to 60ºC to melt wax and ensure tissue adherence to the slide. Slides were 
then subjected to standard rehydration and antigen retrieval was carried out for five minutes in 
boiling 10 mM sodium citrate buffer pH 6, .05% Tween-20 using a pressure cooker. Slides were 
allowed to cool to room temperature in an ice-cold water bath. Slides were then incubated in 3% 
hydrogen peroxide for 20 minutes at room temperature to block endogenous peroxidases. 
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Slides were blocked in 1.5% horse serum and 2% animal free blocker (Vector Laboratories, SP-
5030) for 1 hour at room temperature. Malondialdehyde-stained slides however were blocked in 
5% BSA. Slides were then stained with the appropriate antibody: Cleaved caspase-3 (Cell 
Signaling, 9664S), 1:100 dilution; Ki67 (Cell Signaling, 12202S), 1:100 dilution; phosphohistone-
H3 (Cell Signaling, 9716S), 1:100 dilution; malondialdehyde (Abcam, ab6463), 1:500. Primary 
antibody incubation was carried out overnight at 4ºC. Slides were then washed 3x with PBS-T 
and incubated with the appropriate secondary antibody for 30 minutes at room temperature. 
Staining was developed using the DAB reagent (Vector Labs, VV-93951085).  
Histological staining on paraffin sections (hematoxylin and eosin, Masson’s Trichrome, and 
Movatt’s Pentachrome) were carried out using standard protocols. Following digital capture on 
Olympus BX51, histology images were processed using Affinity Photo software, using three 
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